<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">93666</article-id>
<article-id pub-id-type="doi">10.7554/eLife.93666</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.93666.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.4</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Genetics and Genomics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Novel risk loci for COVID-19 hospitalization among admixed American populations</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Diz-de Almeida</surname>
<given-names>Silvia</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a13">13</xref>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cruz</surname>
<given-names>Raquel</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a13">13</xref>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Luchessi</surname>
<given-names>Andre D</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lorenzo-Salazar</surname>
<given-names>José M</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Heredia</surname>
<given-names>Miguel López</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Quintela</surname>
<given-names>Inés</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>González-Montelongo</surname>
<given-names>Rafaela</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Silbiger</surname>
<given-names>Vivian N</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Porras</surname>
<given-names>Marta Sevilla</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tenorio Castaño</surname>
<given-names>Jair Antonio</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nevado</surname>
<given-names>Julian</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aguado</surname>
<given-names>Jose María</given-names>
</name>
<xref ref-type="aff" rid="a8">8</xref>
<xref ref-type="aff" rid="a9">9</xref>
<xref ref-type="aff" rid="a10">10</xref>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aguilar</surname>
<given-names>Carlos</given-names>
</name>
<xref ref-type="aff" rid="a12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aguilera-Albesa</surname>
<given-names>Sergio</given-names>
</name>
<xref ref-type="aff" rid="a13">13</xref>
<xref ref-type="aff" rid="a14">14</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almadana</surname>
<given-names>Virginia</given-names>
</name>
<xref ref-type="aff" rid="a15">15</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almoguera</surname>
<given-names>Berta</given-names>
</name>
<xref ref-type="aff" rid="a16">16</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alvarez</surname>
<given-names>Nuria</given-names>
</name>
<xref ref-type="aff" rid="a17">17</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Andreu-Bernabeu</surname>
<given-names>Álvaro</given-names>
</name>
<xref ref-type="aff" rid="a18">18</xref>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arana-Arri</surname>
<given-names>Eunate</given-names>
</name>
<xref ref-type="aff" rid="a19">19</xref>
<xref ref-type="aff" rid="a20">20</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arango</surname>
<given-names>Celso</given-names>
</name>
<xref ref-type="aff" rid="a18">18</xref>
<xref ref-type="aff" rid="a21">21</xref>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arranz</surname>
<given-names>María J</given-names>
</name>
<xref ref-type="aff" rid="a22">22</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Artiga</surname>
<given-names>Maria-Jesus</given-names>
</name>
<xref ref-type="aff" rid="a23">23</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baptista-Rosas</surname>
<given-names>Raúl C</given-names>
</name>
<xref ref-type="aff" rid="a24">24</xref>
<xref ref-type="aff" rid="a25">25</xref>
<xref ref-type="aff" rid="a26">26</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Barreda- Sánchez</surname>
<given-names>María</given-names>
</name>
<xref ref-type="aff" rid="a27">27</xref>
<xref ref-type="aff" rid="a28">28</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Belhassen-Garcia</surname>
<given-names>Moncef</given-names>
</name>
<xref ref-type="aff" rid="a29">29</xref>
<xref ref-type="aff" rid="a30">30</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bezerra</surname>
<given-names>Joao F</given-names>
</name>
<xref ref-type="aff" rid="a31">31</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bezerra</surname>
<given-names>Marcos AC</given-names>
</name>
<xref ref-type="aff" rid="a32">32</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boix-Palop</surname>
<given-names>Lucía</given-names>
</name>
<xref ref-type="aff" rid="a33">33</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brion</surname>
<given-names>María</given-names>
</name>
<xref ref-type="aff" rid="a34">34</xref>
<xref ref-type="aff" rid="a35">35</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brugada</surname>
<given-names>Ramón</given-names>
</name>
<xref ref-type="aff" rid="a36">36</xref>
<xref ref-type="aff" rid="a37">37</xref>
<xref ref-type="aff" rid="a35">35</xref>
<xref ref-type="aff" rid="a38">38</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bustos</surname>
<given-names>Matilde</given-names>
</name>
<xref ref-type="aff" rid="a39">39</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Calderón</surname>
<given-names>Enrique J</given-names>
</name>
<xref ref-type="aff" rid="a39">39</xref>
<xref ref-type="aff" rid="a40">40</xref>
<xref ref-type="aff" rid="a41">41</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carbonell</surname>
<given-names>Cristina</given-names>
</name>
<xref ref-type="aff" rid="a42">42</xref>
<xref ref-type="aff" rid="a30">30</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Castano</surname>
<given-names>Luis</given-names>
</name>
<xref ref-type="aff" rid="a19">19</xref>
<xref ref-type="aff" rid="a43">43</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a44">44</xref>
<xref ref-type="aff" rid="a45">45</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Castelao</surname>
<given-names>Jose E</given-names>
</name>
<xref ref-type="aff" rid="a46">46</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conde-Vicente</surname>
<given-names>Rosa</given-names>
</name>
<xref ref-type="aff" rid="a47">47</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cordero-Lorenzana</surname>
<given-names>M Lourdes</given-names>
</name>
<xref ref-type="aff" rid="a48">48</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cortes-Sanchez</surname>
<given-names>Jose L</given-names>
</name>
<xref ref-type="aff" rid="a49">49</xref>
<xref ref-type="aff" rid="a50">50</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Corton</surname>
<given-names>Marta</given-names>
</name>
<xref ref-type="aff" rid="a16">16</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Darnaude</surname>
<given-names>M Teresa</given-names>
</name>
<xref ref-type="aff" rid="a51">51</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Martino-Rodríguez</surname>
<given-names>Alba</given-names>
</name>
<xref ref-type="aff" rid="a52">52</xref>
<xref ref-type="aff" rid="a53">53</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>del Campo-Pérez</surname>
<given-names>Victor</given-names>
</name>
<xref ref-type="aff" rid="a54">54</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Bustamante</surname>
<given-names>Aranzazu Diaz</given-names>
</name>
<xref ref-type="aff" rid="a51">51</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Domínguez-Garrido</surname>
<given-names>Elena</given-names>
</name>
<xref ref-type="aff" rid="a55">55</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eirós</surname>
<given-names>Rocío</given-names>
</name>
<xref ref-type="aff" rid="a56">56</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fariñas</surname>
<given-names>María Carmen</given-names>
</name>
<xref ref-type="aff" rid="a57">57</xref>
<xref ref-type="aff" rid="a58">58</xref>
<xref ref-type="aff" rid="a59">59</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernandez-Nestosa</surname>
<given-names>María J</given-names>
</name>
<xref ref-type="aff" rid="a60">60</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernández-Robelo</surname>
<given-names>Uxía</given-names>
</name>
<xref ref-type="aff" rid="a61">61</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernández-Rodríguez</surname>
<given-names>Amanda</given-names>
</name>
<xref ref-type="aff" rid="a62">62</xref>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernández-Villa</surname>
<given-names>Tania</given-names>
</name>
<xref ref-type="aff" rid="a63">63</xref>
<xref ref-type="aff" rid="a41">41</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gago-Domínguez</surname>
<given-names>Manuela</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="aff" rid="a64">64</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gil-Fournier</surname>
<given-names>Belén</given-names>
</name>
<xref ref-type="aff" rid="a65">65</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gómez-Arrue</surname>
<given-names>Javier</given-names>
</name>
<xref ref-type="aff" rid="a52">52</xref>
<xref ref-type="aff" rid="a53">53</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Álvarez</surname>
<given-names>Beatriz González</given-names>
</name>
<xref ref-type="aff" rid="a52">52</xref>
<xref ref-type="aff" rid="a53">53</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bernaldo de Quirós</surname>
<given-names>Fernan Gonzalez</given-names>
</name>
<xref ref-type="aff" rid="a66">66</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>González-Neira</surname>
<given-names>Anna</given-names>
</name>
<xref ref-type="aff" rid="a17">17</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>González-Peñas</surname>
<given-names>Javier</given-names>
</name>
<xref ref-type="aff" rid="a18">18</xref>
<xref ref-type="aff" rid="a10">10</xref>
<xref ref-type="aff" rid="a21">21</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gutiérrez-Bautista</surname>
<given-names>Juan F</given-names>
</name>
<xref ref-type="aff" rid="a67">67</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Herrero</surname>
<given-names>María José</given-names>
</name>
<xref ref-type="aff" rid="a68">68</xref>
<xref ref-type="aff" rid="a69">69</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Herrero-Gonzalez</surname>
<given-names>Antonio</given-names>
</name>
<xref ref-type="aff" rid="a70">70</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jimenez-Sousa</surname>
<given-names>María A</given-names>
</name>
<xref ref-type="aff" rid="a62">62</xref>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lattig</surname>
<given-names>María Claudia</given-names>
</name>
<xref ref-type="aff" rid="a71">71</xref>
<xref ref-type="aff" rid="a72">72</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Borja</surname>
<given-names>Anabel Liger</given-names>
</name>
<xref ref-type="aff" rid="a73">73</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lopez-Rodriguez</surname>
<given-names>Rosario</given-names>
</name>
<xref ref-type="aff" rid="a16">16</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a74">74</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mancebo</surname>
<given-names>Esther</given-names>
</name>
<xref ref-type="aff" rid="a75">75</xref>
<xref ref-type="aff" rid="a76">76</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martín-López</surname>
<given-names>Caridad</given-names>
</name>
<xref ref-type="aff" rid="a73">73</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martín</surname>
<given-names>Vicente</given-names>
</name>
<xref ref-type="aff" rid="a63">63</xref>
<xref ref-type="aff" rid="a41">41</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez-Nieto</surname>
<given-names>Oscar</given-names>
</name>
<xref ref-type="aff" rid="a77">77</xref>
<xref ref-type="aff" rid="a72">72</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez-Lopez</surname>
<given-names>Iciar</given-names>
</name>
<xref ref-type="aff" rid="a78">78</xref>
<xref ref-type="aff" rid="a79">79</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez-Resendez</surname>
<given-names>Michel F</given-names>
</name>
<xref ref-type="aff" rid="a49">49</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez-Perez</surname>
<given-names>Ángel</given-names>
</name>
<xref ref-type="aff" rid="a80">80</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mazzeu</surname>
<given-names>Juliana F</given-names>
</name>
<xref ref-type="aff" rid="a81">81</xref>
<xref ref-type="aff" rid="a82">82</xref>
<xref ref-type="aff" rid="a83">83</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Macías</surname>
<given-names>Eleuterio Merayo</given-names>
</name>
<xref ref-type="aff" rid="a84">84</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Minguez</surname>
<given-names>Pablo</given-names>
</name>
<xref ref-type="aff" rid="a16">16</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cuerda</surname>
<given-names>Victor Moreno</given-names>
</name>
<xref ref-type="aff" rid="a85">85</xref>
<xref ref-type="aff" rid="a86">86</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oliveira</surname>
<given-names>Silviene F</given-names>
</name>
<xref ref-type="aff" rid="a87">87</xref>
<xref ref-type="aff" rid="a88">88</xref>
<xref ref-type="aff" rid="a83">83</xref>
<xref ref-type="aff" rid="a89">89</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ortega-Paino</surname>
<given-names>Eva</given-names>
</name>
<xref ref-type="aff" rid="a23">23</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parellada</surname>
<given-names>Mara</given-names>
</name>
<xref ref-type="aff" rid="a18">18</xref>
<xref ref-type="aff" rid="a21">21</xref>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paz-Artal</surname>
<given-names>Estela</given-names>
</name>
<xref ref-type="aff" rid="a75">75</xref>
<xref ref-type="aff" rid="a76">76</xref>
<xref ref-type="aff" rid="a90">90</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Santos</surname>
<given-names>Ney PC</given-names>
</name>
<xref ref-type="aff" rid="a91">91</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pérez-Matute</surname>
<given-names>Patricia</given-names>
</name>
<xref ref-type="aff" rid="a92">92</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perez</surname>
<given-names>Patricia</given-names>
</name>
<xref ref-type="aff" rid="a93">93</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pérez-Tomás</surname>
<given-names>M Elena</given-names>
</name>
<xref ref-type="aff" rid="a27">27</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perucho</surname>
<given-names>Teresa</given-names>
</name>
<xref ref-type="aff" rid="a94">94</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pinsach-Abuin</surname>
<given-names>Mel Lina</given-names>
</name>
<xref ref-type="aff" rid="a36">36</xref>
<xref ref-type="aff" rid="a35">35</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pita</surname>
<given-names>Guillermo</given-names>
</name>
<xref ref-type="aff" rid="a17">17</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pompa-Mera</surname>
<given-names>Ericka N</given-names>
</name>
<xref ref-type="aff" rid="a95">95</xref>
<xref ref-type="aff" rid="a96">96</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Porras-Hurtado</surname>
<given-names>Gloria L</given-names>
</name>
<xref ref-type="aff" rid="a97">97</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pujol</surname>
<given-names>Aurora</given-names>
</name>
<xref ref-type="aff" rid="a98">98</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a99">99</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>León</surname>
<given-names>Soraya Ramiro</given-names>
</name>
<xref ref-type="aff" rid="a65">65</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Resino</surname>
<given-names>Salvador</given-names>
</name>
<xref ref-type="aff" rid="a62">62</xref>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernandes</surname>
<given-names>Marianne R</given-names>
</name>
<xref ref-type="aff" rid="a91">91</xref>
<xref ref-type="aff" rid="a100">100</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodríguez-Ruiz</surname>
<given-names>Emilio</given-names>
</name>
<xref ref-type="aff" rid="a101">101</xref>
<xref ref-type="aff" rid="a64">64</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodriguez-Artalejo</surname>
<given-names>Fernando</given-names>
</name>
<xref ref-type="aff" rid="a102">102</xref>
<xref ref-type="aff" rid="a103">103</xref>
<xref ref-type="aff" rid="a41">41</xref>
<xref ref-type="aff" rid="a104">104</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodriguez-Garcia</surname>
<given-names>José A</given-names>
</name>
<xref ref-type="aff" rid="a105">105</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruiz-Cabello</surname>
<given-names>Francisco</given-names>
</name>
<xref ref-type="aff" rid="a67">67</xref>
<xref ref-type="aff" rid="a106">106</xref>
<xref ref-type="aff" rid="a107">107</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruiz-Hornillos</surname>
<given-names>Javier</given-names>
</name>
<xref ref-type="aff" rid="a108">108</xref>
<xref ref-type="aff" rid="a109">109</xref>
<xref ref-type="aff" rid="a110">110</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ryan</surname>
<given-names>Pablo</given-names>
</name>
<xref ref-type="aff" rid="a111">111</xref>
<xref ref-type="aff" rid="a112">112</xref>
<xref ref-type="aff" rid="a113">113</xref>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Soria</surname>
<given-names>José Manuel</given-names>
</name>
<xref ref-type="aff" rid="a80">80</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Souto</surname>
<given-names>Juan Carlos</given-names>
</name>
<xref ref-type="aff" rid="a114">114</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tamayo</surname>
<given-names>Eduardo</given-names>
</name>
<xref ref-type="aff" rid="a115">115</xref>
<xref ref-type="aff" rid="a116">116</xref>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tamayo-Velasco</surname>
<given-names>Alvaro</given-names>
</name>
<xref ref-type="aff" rid="a117">117</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taracido-Fernandez</surname>
<given-names>Juan Carlos</given-names>
</name>
<xref ref-type="aff" rid="a70">70</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Teper</surname>
<given-names>Alejandro</given-names>
</name>
<xref ref-type="aff" rid="a118">118</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Torres-Tobar</surname>
<given-names>Lilian</given-names>
</name>
<xref ref-type="aff" rid="a119">119</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Urioste</surname>
<given-names>Miguel</given-names>
</name>
<xref ref-type="aff" rid="a120">120</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Valencia-Ramos</surname>
<given-names>Juan</given-names>
</name>
<xref ref-type="aff" rid="a121">121</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yáñez</surname>
<given-names>Zuleima</given-names>
</name>
<xref ref-type="aff" rid="a122">122</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zarate</surname>
<given-names>Ruth</given-names>
</name>
<xref ref-type="aff" rid="a123">123</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Rojas</surname>
<given-names>Itziar</given-names>
</name>
<xref ref-type="aff" rid="a124">124</xref>
<xref ref-type="aff" rid="a125">125</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruiz</surname>
<given-names>Agustín</given-names>
</name>
<xref ref-type="aff" rid="a124">124</xref>
<xref ref-type="aff" rid="a125">125</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sánchez</surname>
<given-names>Pascual</given-names>
</name>
<xref ref-type="aff" rid="a126">126</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Real</surname>
<given-names>Luis Miguel</given-names>
</name>
<xref ref-type="aff" rid="a127">127</xref>
</contrib>
<contrib contrib-type="author">
<collab>SCOURGE Cohort Group</collab>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guillen-Navarro</surname>
<given-names>Encarna</given-names>
</name>
<xref ref-type="aff" rid="a27">27</xref>
<xref ref-type="aff" rid="a128">128</xref>
<xref ref-type="aff" rid="a129">129</xref>
<xref ref-type="aff" rid="a130">130</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ayuso</surname>
<given-names>Carmen</given-names>
</name>
<xref ref-type="aff" rid="a16">16</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parra</surname>
<given-names>Esteban</given-names>
</name>
<xref ref-type="aff" rid="a131">131</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Riancho</surname>
<given-names>José A</given-names>
</name>
<xref ref-type="aff" rid="a57">57</xref>
<xref ref-type="aff" rid="a58">58</xref>
<xref ref-type="aff" rid="a59">59</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rojas-Martinez</surname>
<given-names>Augusto</given-names>
</name>
<xref ref-type="aff" rid="a132">132</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" corresp="yes">
<name>
<surname>Flores</surname>
<given-names>Carlos</given-names>
</name>
<email>cflores@ull.edu.es</email>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a133">133</xref>
<xref ref-type="aff" rid="a134">134</xref>
<xref ref-type="aff" rid="a135">135</xref>
<xref ref-type="author-notes" rid="n1">136</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Lapunzina</surname>
<given-names>Pablo</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="aff" rid="a7">7</xref>
<xref ref-type="author-notes" rid="n1">136</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" corresp="yes">
<name>
<surname>Carracedo</surname>
<given-names>Ángel</given-names>
</name>
<email>angel.carracedo@usc.es</email>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="aff" rid="a64">64</xref>
<xref ref-type="author-notes" rid="n1">136</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela</institution>, <city>Santiago de Compostela</city>, <country>Spain</country></aff>
<aff id="a2"><label>2</label><institution>CIBERER, ISCIII</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a3"><label>3</label><institution>Universidade Federal do Rio Grande do Norte, Departamento de Analises Clinicas e Toxicologicas</institution>, <city>Natal</city>, <country>Brazil</country></aff>
<aff id="a4"><label>4</label><institution>Genomics Division, Instituto Tecnológico y de Energías Renovables</institution>, <city>Santa Cruz de Tenerife</city>, <country>Spain</country></aff>
<aff id="a5"><label>5</label><institution>Fundación Pública Galega de Medicina Xenómica, Sistema Galego de Saúde (SERGAS) Santiago de Compostela</institution>, <country>Spain</country></aff>
<aff id="a6"><label>6</label><institution>Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz-IDIPAZ</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a7"><label>7</label><institution>ERN-ITHACA-European Reference Network</institution></aff>
<aff id="a8"><label>8</label><institution>Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12)</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a9"><label>9</label><institution>Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0002), Instituto de Salud Carlos III</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a10"><label>10</label><institution>School of Medicine, Universidad Complutense</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a11"><label>11</label><institution>CIBERINFEC, ISCIII</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a12"><label>12</label><institution>Hospital General Santa Bárbara de Soria</institution>, Soria, <country>Spain</country></aff>
<aff id="a13"><label>13</label><institution>Pediatric Neurology Unit, Department of Pediatrics, Navarra Health Service Hospital</institution>, <city>Pamplona</city>, <country>Spain</country></aff>
<aff id="a14"><label>14</label><institution>Navarra Health Service, NavarraBioMed Research Group</institution>, <city>Pamplona</city>, <country>Spain</country></aff>
<aff id="a15"><label>15</label><institution>Hospital Universitario Virgen Macarena, Neumología</institution>, <city>Seville</city>, <country>Spain</country></aff>
<aff id="a16"><label>16</label><institution>Department of Genetics &amp; Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM)</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a17"><label>17</label><institution>Spanish National Cancer Research Centre, Human Genotyping-CEGEN Unit</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a18"><label>18</label><institution>Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón (IiSGM)</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a19"><label>19</label><institution>Biocruces Bizkai HRI</institution>, Bizkaia, <country>Spain</country></aff>
<aff id="a20"><label>20</label><institution>Cruces University Hospital</institution>, Osakidetza, Bizkaia, <country>Spain</country></aff>
<aff id="a21"><label>21</label><institution>Centre for Biomedical Network Research on Mental Health (CIBERSAM), Instituto de Salud Carlos III</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a22"><label>22</label><institution>Fundació Docència I Recerca Mutua Terrassa</institution>, <city>Barcelona</city>, <country>Spain</country></aff>
<aff id="a23"><label>23</label><institution>Spanish National Cancer Research Center, CNIO Biobank</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a24"><label>24</label><institution>Hospital General de Occidente</institution>, Zapopan Jalisco, <country>Mexico</country></aff>
<aff id="a25"><label>25</label><institution>Centro Universitario de Tonalá, Universidad de Guadalajara</institution>, Tonalá Jalisco, <country>Mexico</country></aff>
<aff id="a26"><label>26</label><institution>Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara</institution>, Tonalá Jalisco, <country>Mexico</country></aff>
<aff id="a27"><label>27</label><institution>Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca)</institution>, <city>Murcia</city>, <country>Spain</country></aff>
<aff id="a28"><label>28</label><institution>Universidad Católica San Antonio de Murcia (UCAM)</institution>, <city>Murcia</city>, <country>Spain</country></aff>
<aff id="a29"><label>29</label><institution>Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna-Unidad de Enfermedades Infecciosas</institution>, <city>Salamanca</city>, <country>Spain</country></aff>
<aff id="a30"><label>30</label><institution>Universidad de Salamanca</institution>, <city>Salamanca</city>, <country>Spain</country></aff>
<aff id="a31"><label>31</label><institution>Escola Tecnica de Saúde, Laboratorio de Vigilancia Molecular Aplicada</institution>, <country>Brazil</country></aff>
<aff id="a32"><label>32</label><institution>Federal University of Pernambuco, Genetics Postgraduate Program</institution>, Recife, PE, <country>Brazil</country></aff>
<aff id="a33"><label>33</label><institution>Hospital Universitario Mutua Terrassa</institution>, <city>Barcelona</city>, <country>Spain</country></aff>
<aff id="a34"><label>34</label><institution>Instituto de Investigación Sanitaria de Santiago (IDIS), Xenética Cardiovascular, Santiago de Compostela</institution>, <country>Spain</country></aff>
<aff id="a35"><label>35</label><institution>CIBERCV, ISCIII</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a36"><label>36</label><institution>Cardiovascular Genetics Center, Institut d’Investigació Biomèdica Girona (IDIBGI)</institution>, <city>Girona</city>, <country>Spain</country></aff>
<aff id="a37"><label>37</label><institution>Medical Science Department, School of Medicine, University of Girona</institution>, <city>Girona</city>, <country>Spain</country></aff>
<aff id="a38"><label>38</label><institution>Hospital Josep Trueta, Cardiology Service</institution>, <city>Girona</city>, <country>Spain</country></aff>
<aff id="a39"><label>39</label><institution>Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas (CSIC)- University of Seville- Virgen del Rocio University Hospital</institution>, <city>Seville</city>, <country>Spain</country></aff>
<aff id="a40"><label>40</label><institution>Departamento de Medicina, Hospital Universitario Virgen del Rocío, Universidad de Sevilla</institution>, <city>Seville</city>, <country>Spain</country></aff>
<aff id="a41"><label>41</label><institution>CIBERESP, ISCIII</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a42"><label>42</label><institution>Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna</institution>, <city>Salamanca</city>, <country>Spain</country></aff>
<aff id="a43"><label>43</label><institution>Osakidetza, Cruces University Hospital</institution>, Bizkaia, <country>Spain</country></aff>
<aff id="a44"><label>44</label><institution>Centre for Biomedical Network Research on Diabetes and Metabolic Associated Diseases (CIBERDEM), Instituto de Salud Carlos III</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a45"><label>45</label><institution>University of Pais Vasco, UPV/EHU</institution>, Bizkaia, <country>Spain</country></aff>
<aff id="a46"><label>46</label><institution>Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de Xestion Integrada de Vigo-Servizo Galego de Saúde</institution>, Vigo, <country>Spain</country></aff>
<aff id="a47"><label>47</label><institution>Hospital Universitario Río Hortega</institution>, <city>Valladolid</city>, <country>Spain</country></aff>
<aff id="a48"><label>48</label><institution>Servicio de Medicina intensiva, Complejo Hospitalario Universitario de A Coruña (CHUAC), Sistema Galego de Saúde (SERGAS)</institution>, <city>A Coruña</city>, <country>Spain</country></aff>
<aff id="a49"><label>49</label><institution>Tecnológico de Monterrey</institution>, Monterrey, <country>Mexico</country></aff>
<aff id="a50"><label>50</label><institution>Otto von Guericke University, Departament of Microgravity and Translational Regenerative Medicine</institution>, Magdeburg, <country>Germany</country></aff>
<aff id="a51"><label>51</label><institution>Hospital Universitario Mostoles, Unidad de Genética</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a52"><label>52</label><institution>Instituto Aragonés de Ciencias de la Salud (IACS)</institution>, Zaragoza, <country>Spain</country></aff>
<aff id="a53"><label>53</label><institution>Instituto Investigación Sanitaria Aragón (IIS-Aragon)</institution>, Zaragoza, <country>Spain</country></aff>
<aff id="a54"><label>54</label><institution>Preventive Medicine Department, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de Xestion Integrada de Vigo-Servizo Galego de Saúde</institution>, Vigo, <country>Spain</country></aff>
<aff id="a55"><label>55</label><institution>Unidad Diagnóstico Molecular. Fundación Rioja Salud</institution>, La Rioja, <country>Spain</country></aff>
<aff id="a56"><label>56</label><institution>Hospital Universitario de Salamanca-IBSAL</institution>, Servicio de Cardiología, <city>Salamanca</city>, <country>Spain</country></aff>
<aff id="a57"><label>57</label><institution>IDIVAL</institution>, <city>Cantabria</city>, <country>Spain</country></aff>
<aff id="a58"><label>58</label><institution>Universidad de Cantabria</institution>, <city>Cantabria</city>, <country>Spain</country></aff>
<aff id="a59"><label>59</label><institution>Hospital U M Valdecilla</institution>, <city>Cantabria</city>, <country>Spain</country></aff>
<aff id="a60"><label>60</label><institution>Universidad Nacional de Asunción</institution>, Facultad de Politécnica, <country>Paraguay</country></aff>
<aff id="a61"><label>61</label><institution>Urgencias Hospitalarias, Complejo Hospitalario Universitario de A Coruña (CHUAC), Sistema Galego de Saúde (SERGAS)</institution>, <city>A Coruña</city>, <country>Spain</country></aff>
<aff id="a62"><label>62</label><institution>Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III (ISCIII)</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a63"><label>63</label><institution>Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS) - Instituto de Biomedicina (IBIOMED), Universidad de León</institution>, <city>León</city>, <country>Spain</country></aff>
<aff id="a64"><label>64</label><institution>IDIS</institution></aff>
<aff id="a65"><label>65</label><institution>Hospital Universitario de Getafe</institution>, Servicio de Genética, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a66"><label>66</label><institution>Ministerio de Salud Ciudad de Buenos Aires</institution>, Buenos Aires, <country>Argentina</country></aff>
<aff id="a67"><label>67</label><institution>Hospital Universitario Virgen de las Nieves</institution>, Servicio de Análisis Clínicos e Inmunología, <city>Granada</city>, <country>Spain</country></aff>
<aff id="a68"><label>68</label><institution>IIS La Fe, Plataforma de Farmacogenética</institution>, Valencia, <country>Spain</country></aff>
<aff id="a69"><label>69</label><institution>Universidad de Valencia, Departamento de Farmacología</institution>, Valencia, <country>Spain</country></aff>
<aff id="a70"><label>70</label><institution>Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM)</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a71"><label>71</label><institution>Universidad de los Andes, Facultad de Ciencias</institution>, <city>Bogotá</city>, <country>Colombia</country></aff>
<aff id="a72"><label>72</label><institution>SIGEN Alianza Universidad de los Andes - Fundación Santa Fe de Bogotá</institution>, <city>Bogotá</city>, <country>Colombia</country></aff>
<aff id="a73"><label>73</label><institution>Hospital General de Segovia, Medicina Intensiva</institution>, Segovia, <country>Spain</country></aff>
<aff id="a74"><label>74</label><institution>Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe</institution>, Boadilla del Monte, <country>España</country></aff>
<aff id="a75"><label>75</label><institution>Hospital Universitario 12 de Octubre, Department of Immunology</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a76"><label>76</label><institution>Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Transplant Immunology and Immunodeficiencies Group</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a77"><label>77</label><institution>Fundación Santa Fe de Bogota, Departamento Patologia y Laboratorios</institution>, <city>Bogotá</city>, <country>Colombia</country></aff>
<aff id="a78"><label>78</label><institution>Unidad de Genética y Genómica Islas Baleares</institution>, <city>Islas Baleares</city>, <country>Spain</country></aff>
<aff id="a79"><label>79</label><institution>Hospital Universitario Son Espases, Unidad de Diagnóstico Molecular y Genética Clínica</institution>, <city>Islas Baleares</city>, <country>Spain</country></aff>
<aff id="a80"><label>80</label><institution>Genomics of Complex Diseases Unit, Research Institute of Hospital de la Santa Creu i Sant Pau, IIB Sant Pau</institution>, <city>Barcelona</city>, <country>Spain</country></aff>
<aff id="a81"><label>81</label><institution>Universidade de Brasília, Faculdade de Medicina</institution>, <country>Brazil</country></aff>
<aff id="a82"><label>82</label><institution>Programa de Pós-Graduação em Ciências Médicas (UnB)</institution>, <country>Brazil</country></aff>
<aff id="a83"><label>83</label><institution>Programa de Pós-Graduação em Ciencias da Saude (UnB)</institution>, <country>Brazil</country></aff>
<aff id="a84"><label>84</label><institution>Hospital El Bierzo, Unidad Cuidados Intensivos</institution>, <city>León</city>, <country>Spain</country></aff>
<aff id="a85"><label>85</label><institution>Hospital Universitario Mostoles, Medicina Interna</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a86"><label>86</label><institution>Universidad Francisco de Vitoria</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a87"><label>87</label><institution>Departamento de Genética e Morfologia, Instituto de Ciências Biológicas, Universidade de Brasília</institution>, <country>Brazil</country></aff>
<aff id="a88"><label>88</label><institution>Programa de Pós-Graduação em Biologia Animal (UnB)</institution>, <country>Brazil</country></aff>
<aff id="a89"><label>89</label><institution>Programa de Pós-Graduação Profissional em Ensino de Biologia (UnB)</institution>, <country>Brazil</country></aff>
<aff id="a90"><label>90</label><institution>Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and ENT</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a91"><label>91</label><institution>Universidade Federal do Pará, Núcleo de Pesquisas em Oncologia</institution>, Belém, Pará, <country>Brazil</country></aff>
<aff id="a92"><label>92</label><institution>Infectious Diseases, Microbiota and Metabolism Unit, CSIC Associated Unit, Center for Biomedical Research of La Rioja (CIBIR)</institution>, Logroño, <country>Spain</country></aff>
<aff id="a93"><label>93</label><institution>Inditex</institution>, <city>A Coruña</city>, <country>Spain</country></aff>
<aff id="a94"><label>94</label><institution>GENYCA</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a95"><label>95</label><institution>Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional Siglo XXI, Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias</institution>, <city>Mexico City</city>, <country>Mexico</country></aff>
<aff id="a96"><label>96</label><institution>Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional La Raza. Hospital de Infectología</institution>, <city>Mexico City</city>, <country>Mexico</country></aff>
<aff id="a97"><label>97</label><institution>Clinica Comfamiliar Risaralda</institution>, <city>Pereira</city>, <country>Colombia</country></aff>
<aff id="a98"><label>98</label><institution>Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory, L’Hospitalet de Llobregat</institution>, <country>Spain</country></aff>
<aff id="a99"><label>99</label><institution>Catalan Institution of Research and Advanced Studies (ICREA)</institution>, <city>Barcelona</city>, <country>Spain</country></aff>
<aff id="a100"><label>100</label><institution>Hospital Ophir Loyola, Departamento de Ensino e Pesquisa</institution>, Belém, Pará, <country>Brazil</country></aff>
<aff id="a101"><label>101</label><institution>Unidad de Cuidados Intensivos, Hospital Clínico Universitario de Santiago (CHUS), Sistema Galego de Saúde (SERGAS)</institution>, <city>Santiago de Compostela</city>, <country>Spain</country></aff>
<aff id="a102"><label>102</label><institution>Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a103"><label>103</label><institution>IdiPaz (Instituto de Investigación Sanitaria Hospital Universitario La Paz)</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a104"><label>104</label><institution>IMDEA-Food Institute, CEI UAM+CSIC</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a105"><label>105</label><institution>Complejo Asistencial Universitario de León</institution>, <city>León</city>, <country>Spain</country></aff>
<aff id="a106"><label>106</label><institution>Instituto de Investigación Biosanitaria de Granada (ibs GRANADA)</institution>, <city>Granada</city>, <country>Spain</country></aff>
<aff id="a107"><label>107</label><institution>Universidad de Granada, Departamento Bioquímica, Biología Molecular e Inmunología III</institution>, <city>Granada</city>, <country>Spain</country></aff>
<aff id="a108"><label>108</label><institution>Hospital Infanta Elena, Allergy Unit</institution>, Valdemoro, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a109"><label>109</label><institution>Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM)</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a110"><label>110</label><institution>Faculty of Medicine, Universidad Francisco de Vitoria</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a111"><label>111</label><institution>Hospital Universitario Infanta Leonor</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a112"><label>112</label><institution>Complutense University of Madrid</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a113"><label>113</label><institution>Gregorio Marañón Health Research Institute (IiSGM)</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a114"><label>114</label><institution>Haemostasis and Thrombosis Unit, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau</institution>, <city>Barcelona</city>, <country>Spain</country></aff>
<aff id="a115"><label>115</label><institution>Hospital Clinico Universitario de Valladolid, Servicio de Anestesiologia y Reanimación</institution>, <city>Valladolid</city>, <country>Spain</country></aff>
<aff id="a116"><label>116</label><institution>Universidad de Valladolid, Departamento de Cirugía</institution>, <city>Valladolid</city>, <country>Spain</country></aff>
<aff id="a117"><label>117</label><institution>Hospital Clinico Universitario de Valladolid, Servicio de Hematologia y Hemoterapia</institution>, <city>Valladolid</city>, <country>Spain</country></aff>
<aff id="a118"><label>118</label><institution>Hospital de Niños Ricardo Gutierrez</institution>, Buenos Aires, <country>Argentina</country></aff>
<aff id="a119"><label>119</label><institution>Fundación Universitaria de Ciencias de la Salud</institution></aff>
<aff id="a120"><label>120</label><institution>Spanish National Cancer Research Centre, Familial Cancer Clinical Unit</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a121"><label>121</label><institution>University Hospital of Burgos</institution>, Burgos, <country>Spain</country></aff>
<aff id="a122"><label>122</label><institution>Universidad Simón Bolívar, Facultad de Ciencias de la Salud</institution>, Barranquilla, <country>Colombia</country></aff>
<aff id="a123"><label>123</label><institution>Centro para el Desarrollo de la Investigación Científica</institution>, <country>Paraguay</country></aff>
<aff id="a124"><label>124</label><institution>Research Center and Memory clinic, ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya</institution>, <country>Spain</country></aff>
<aff id="a125"><label>125</label><institution>Centre for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a126"><label>126</label><institution>CIEN Foundation/Queen Sofia Foundation Alzheimer Center</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a127"><label>127</label><institution>Hospital Universitario de Valme, Unidad Clínica de Enfermedades Infecciosas y Microbiología</institution>, <city>Sevilla</city>, <country>Spain</country></aff>
<aff id="a128"><label>128</label><institution>Sección Genética Médica - Servicio de Pediatría, Hospital Clínico Universitario Virgen de la Arrixaca, Servicio Murciano de Salud</institution>, <city>Murcia</city>, <country>Spain</country></aff>
<aff id="a129"><label>129</label><institution>Departamento Cirugía, Pediatría, Obstetricia y Ginecología, Facultad de Medicina, Universidad de Murcia (UMU)</institution>, <city>Murcia</city>, <country>Spain</country></aff>
<aff id="a130"><label>130</label><institution>Grupo Clínico Vinculado, Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a131"><label>131</label><institution>Department of Anthropology, University of Toronto at Mississauga</institution>, Mississauga, Ontario, <country>Canada</country></aff>
<aff id="a132"><label>132</label><institution>Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud</institution>, Monterrey, <country>Mexico</country></aff>
<aff id="a133"><label>133</label><institution>Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigación Sanitaria de Canarias</institution>, <city>Santa Cruz de Tenerife</city>, <country>Spain</country></aff>
<aff id="a134"><label>134</label><institution>Centre for Biomedical Network Research on Respiratory Diseases (CIBERES), Instituto de Salud Carlos III</institution>, <city>Madrid</city>, <country>Spain</country></aff>
<aff id="a135"><label>135</label><institution>Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria</institution>, <country>Spain</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Zhao</surname>
<given-names>Siming</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Dartmouth College</institution>
</institution-wrap>
<city>Lebanon</city>
<country>United States of America</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Choi</surname>
<given-names>Murim</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>Seoul National University</institution>
</institution-wrap>
<city>Seoul</city>
<country>Republic of Korea</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>136</label><p>These authors contributed equally: Carlos Flores, Pablo Lapunzina, Ángel Carracedo</p></fn>
<fn fn-type="equal"><label>137</label><p>These authors contributed equally: Silvia Diz-de Almeida, Raquel Cruz</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-02-14">
<day>14</day>
<month>02</month>
<year>2024</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2024-09-05">
<day>05</day>
<month>09</month>
<year>2024</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP93666</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2023-11-06">
<day>06</day>
<month>11</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-02-08">
<day>08</day>
<month>02</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.08.11.23293871"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2024-02-14">
<day>14</day>
<month>02</month>
<year>2024</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.93666.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.93666.1.sa3">eLife assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.93666.1.sa2">Reviewer #1 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.93666.1.sa1">Reviewer #2 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.93666.1.sa0">Reviewer #3 (Public Review):</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Diz-de Almeida et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Diz-de Almeida et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-93666-v2.pdf"/>
<abstract>
<title>Abstract</title>
<p>The genetic basis of severe COVID-19 has been thoroughly studied, and many genetic risk factors shared between populations have been identified. However, reduced sample sizes from non-European groups have limited the discovery of population-specific common risk loci. In this second study nested in the SCOURGE consortium, we conducted a GWAS for COVID-19 hospitalization in admixed Americans, comprising a total of 4,702 hospitalized cases recruited by SCOURGE and seven other participating studies in the COVID-19 Host Genetic Initiative. We identified four genome-wide significant associations, two of which constitute novel loci and were first discovered in Latin American populations (<italic>BAZ2B</italic> and <italic>DDIAS</italic>). A trans-ethnic meta-analysis revealed another novel cross-population risk locus in <italic>CREBBP</italic>. Finally, we assessed the performance of a cross-ancestry polygenic risk score in the SCOURGE admixed American cohort. This study constitutes the largest GWAS for COVID-19 hospitalization in admixed Latin Americans conducted to date. This allowed to reveal novel risk loci and emphasize the need of considering the diversity of populations in genomic research.</p>
</abstract>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>Instituto de Salud Carlos III (COV20_00622 to A.C., COV20/00792 to M.B., COV20_00181 to C.A., COV20_1144 to M.A.J.S. and A.F.R., PI20/00876 to C.F.); European Union (ERDF) &lt;&lt;A way of making Europe&gt;&gt;. Fundacion Amancio Ortega, Banco de Santander (to A.C.), Estrella de Levante S.A. and Colabora Mujer Association (to E.G.-N.) and Obra Social La Caixa (to R.B.); Agencia Estatal de Investigacion (RTC-2017-6471-1 to C.F.), Cabildo Insular de Tenerife (CGIEU0000219140 &lt;&lt;Apuestas cientificas del ITER para colaborar en la lucha contra la COVID-19&gt;&gt; to C.F.) and Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias (PIFIISC20/57 to C.F.).
SD-DA was supported by a Xunta de Galicia predoctoral fellowship.
</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>Ethics and Scientific Committees from the participating centres and by the Galician Ethics Committee Ref 2020/197 gave ethical approval for this work.
Recruitment of patients from IMSS (in Mexico, City), was approved by of the National Comitte of Clinical Research, from Instituto Mexicano del Seguro Social, Mexico (protocol R-2020-785-082).</p><p>I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.</p><p>Yes</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Revised preprint with changes suggested by eLife reviewers. Review file can be found within eLife's posted preprint.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>To date, more than 50 loci associated with COVID-19 susceptibility, hospitalization, and severity have been identified using genome-wide association studies (GWAS)<sup><xref ref-type="bibr" rid="c1">1</xref>,<xref ref-type="bibr" rid="c2">2</xref></sup>. The COVID-19 Host Genetics Initiative (HGI) has made significant efforts<sup><xref ref-type="bibr" rid="c3">3</xref></sup> to augment the power to identify disease loci by recruiting individuals from diverse populations and conducting a trans-ancestry meta-analysis. Despite this, the lack of genetic diversity and a focus on cases of European ancestries still predominate in the studies<sup><xref ref-type="bibr" rid="c4">4</xref>,<xref ref-type="bibr" rid="c5">5</xref></sup>. In addition, while trans-ancestry meta-analyses are a powerful approach for discovering shared genetic risk variants with similar effects across populations<sup><xref ref-type="bibr" rid="c6">6</xref></sup>, they may fail to identify risk variants that have larger effects on particular underrepresented populations. Genetic disease risk has been shaped by the particular evolutionary history of populations and environmental exposures<sup><xref ref-type="bibr" rid="c7">7</xref></sup>. Their action is particularly important for infectious diseases due to the selective constraints that are imposed by host–pathogen interactions<sup><xref ref-type="bibr" rid="c8">8</xref>,<xref ref-type="bibr" rid="c9">9</xref></sup>. Literature examples of this in COVID-19 severity include a <italic>DOCK2</italic> gene variant in East Asians<sup><xref ref-type="bibr" rid="c10">10</xref></sup> and frequent loss-of-function variants in <italic>IFNAR1</italic> and <italic>IFNAR2</italic> genes in Polynesian and Inuit populations, respectively<sup><xref ref-type="bibr" rid="c11">11</xref>,<xref ref-type="bibr" rid="c12">12</xref></sup>.</p>
<p>Including diverse populations in case–control GWAS studies with unrelated participants usually requires a prior classification of individuals in genetically homogeneous groups, which are typically analyzed separately to control the population stratification effects<sup><xref ref-type="bibr" rid="c13">13</xref></sup>. Populations with recent admixture impose an additional challenge to GWASs due to their complex genetic diversity and linkage disequilibrium (LD) patterns, requiring the development of alternative approaches and a careful inspection of results to reduce false positives due to population structure<sup><xref ref-type="bibr" rid="c7">7</xref></sup>. In fact, there are benefits in study power from modeling the admixed ancestries either locally, at the regional scale in the chromosomes, or globally, across the genome, depending on factors such as the heterogeneity of the risk variant in frequencies or the effects among the ancestry strata<sup><xref ref-type="bibr" rid="c14">14</xref></sup>. Despite the development of novel methods specifically tailored for the analysis of admixed populations<sup><xref ref-type="bibr" rid="c15">15</xref></sup>, the lack of a standardized analysis framework and the difficulties in confidently clustering admixed individuals into particular genetic groups often leads to their exclusion from GWAS.</p>
<p>The Spanish Coalition to Unlock Research on Host Genetics on COVID-19 (SCOURGE) recruited COVID-19 patients between March and December 2020 from hospitals across Spain and from March 2020 to July 2021 in Latin America (<ext-link ext-link-type="uri" xlink:href="https://www.scourge-covid.org">https://www.scourge-covid.org</ext-link>). A first GWAS of COVID-19 severity among Spanish patients of European descent revealed novel disease loci and explored age- and sex-varying effects of genetic factors<sup><xref ref-type="bibr" rid="c16">16</xref></sup>. Here, we present the findings of a GWAS meta-analysis in admixed Latin American (AMR) populations, comprising individuals from the SCOURGE Latin-American cohort and the HGI studies, which allowed us to identify two novel severe COVID-19 loci, <italic>BAZ2B</italic> and <italic>DDIAS</italic>. Further analyses modeling the admixture from three genetic ancestral components and performing a trans-ethnic meta-analysis led to the identification of an additional risk locus near <italic>CREBBP</italic>. We finally assessed a cross-ancestry polygenic risk score model with variants associated with critical COVID-19.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Meta-analysis of COVID-19 hospitalization in admixed Americans</title>
<sec id="s2a1">
<title>Study cohorts</title>
<p>Within the SCOURGE consortium, we included 1,608 hospitalized cases and 1,887 controls (not hospitalized COVID-19 patients) from Latin American countries and from recruitments of individuals of Latin American descent conducted in Spain (Supplementary Table 1). Quality control details and estimation of global genetic inferred ancestry (GIA) (Supplementary Figure 1) are described in Methods, whereas clinical and demographic characteristics of patients included in the analysis are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>. Summary statistics from the SCOURGE cohort were obtained under a logistic mixed model with the SAIGE model (Methods). Another seven studies participating in the COVID-19 HGI consortium were included in the meta-analysis of COVID-19 hospitalization in admixed Americans (<xref rid="fig1" ref-type="fig">Figure 1</xref>).</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><title>Demographic characteristics of the SCOURGE Latin American cohort.</title></caption>
<graphic xlink:href="23293871v4_tbl1.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Flow chart of this study.</title></caption>
<graphic xlink:href="23293871v4_fig1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2a2">
<title>GWAS meta-analysis</title>
<p>We performed a fixed-effects GWAS meta-analysis using the inverse of the variance as weights for the overlapping markers. The combined GWAS sample size consisted of 4,702 admixed AMR hospitalized cases and 68,573 controls.</p>
<p>This GWAS meta-analysis revealed genome-wide significant associations at four risk loci (<xref rid="tbl2" ref-type="table">Table 2</xref>, <xref rid="fig2" ref-type="fig">Figure 2</xref>), two of which (<italic>BAZ2B</italic> and <italic>DDIAS</italic>) were novel discoveries. Four lead variants were identified, linked to other 310 variants (Supplementary Tables 2-3). A gene-based association test revealed a significant association in <italic>BAZ2B</italic> and in previously known COVID-19 risk loci: <italic>LZTFL1, XCR1, FYCO1, CCR9</italic>, and <italic>IFNAR2</italic> (Supplementary Table 4).</p>
<table-wrap id="tbl2" orientation="portrait" position="float">
<label>Table 2.</label>
<caption><title>Lead independent variants in the admixed AMR GWAS meta-analysis.</title></caption>
<graphic xlink:href="23293871v4_tbl2.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="23293871v4_tbl2a.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
<table-wrap id="tbl3" orientation="portrait" position="float">
<label>Table 3.</label>
<caption><title>Novel variants in the SC-HGI<sub>ALL</sub> and SC-HGI<sub>3POP</sub> meta-analyses (with respect to HGIv7).</title>
<p>Independent signals after LD clumping.</p></caption>
<graphic xlink:href="23293871v4_tbl3.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><p><bold>A) Manhattan plot for the admixed AMR GWAS meta-analysis.</bold> Probability thresholds at p=5×10<sup>−8</sup> and p=5×10<sup>−5</sup> are indicated by the horizontal lines. Genome-wide significant associations with COVID-19 hospitalizations were found on chromosome 2 (within <italic>BAZ2B</italic>), chromosome 3 (within <italic>LZTFL1</italic>), chromosome 6 (within <italic>FOXP4</italic>), and chromosome 11 (within <italic>DDIAS</italic>). A Quantile–Quantile plot is shown in supplementary Figure 2. <bold>B) Regional association plots for rs1003835 at chromosome 2 and rs77599934 at chromosome 11</bold>; <bold>C) Allele frequency distribution across the 1000 Genomes Project populations for the lead variants rs1003835 and rs77599934</bold>. Retrieved from <italic>The Geography of Genetic Variants Web</italic> or GGV.</p></caption>
<graphic xlink:href="23293871v4_fig2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Located within the <italic>BAZ2B</italic> gene, the sentinel variant rs13003835 is an intronic variant associated with an increased risk of COVID-19 hospitalization (Odds Ratio [OR]=1.20, 95% Confidence Interval [CI]=1.12-1.27, p=3.66×10<sup>−8</sup>). This association was not previously reported in any GWAS of COVID-19 published to date. Interestingly, rs13003835 did not reach significance (p=0.972) in the COVID-19 HGI trans-ancestry meta-analysis including the five population groups<sup><xref ref-type="bibr" rid="c1">1</xref></sup>.</p>
<p>The other novel risk locus is led by the sentinel variant rs77599934, a rare intronic variant located in chromosome 11 within <italic>DDIAS</italic> and associated with the risk of COVID-19 hospitalization (OR=2.27, 95% CI=1.70-3.04, p=2.26×10<sup>−8</sup>).</p>
<p>We also observed a suggestive association with rs2601183 in chromosome 15, which is located between <italic>ZNF774</italic> and <italic>IQGAP1</italic> (allele-G OR=1.20, 95% CI=1.12-1.29, p=6.11×10<sup>−8</sup>, see Supplementary Table 2), which has not yet been reported in any other GWAS of COVID-19 to date.</p>
<p>The GWAS meta-analysis also pinpointed two significant variants at known loci, <italic>LZTFL1</italic> and <italic>FOXP4</italic>. The SNP rs35731912 was previously associated with COVID-19 severity in EUR populations<sup><xref ref-type="bibr" rid="c17">17</xref></sup>, and it was mapped to <italic>LZTFL1</italic>. While rs2477820 is a novel risk variant within the <italic>FOXP4 gene</italic>, it has a moderate LD (<italic>r</italic><sup><xref ref-type="bibr" rid="c2">2</xref></sup>=0.295) with rs2496644, which has been linked to COVID-19 hospitalization<sup><xref ref-type="bibr" rid="c18">18</xref></sup>. This is consistent with the effects of LD in tag-SNPs when conducting GWAS in diverse populations.</p>
<p>None of the lead variants was associated with the comorbidities included in <xref rid="tbl1" ref-type="table">Table 1</xref>.</p>
</sec>
</sec>
<sec id="s2b">
<title>Functional mapping of novel risk variants</title>
<p>Variants belonging to the lead loci were prioritized by positional and expression quantitative trait loci (eQTL) mapping with FUMA, resulting in 31 mapped genes (Supplementary Table 5). Within the region surrounding the lead variant in chromosome 2, FUMA prioritized four genes in addition to <italic>BAZ2B</italic> (<italic>PLA2R1, LY75, WDSUB1</italic>, and <italic>CD302</italic>). rs13003835 (allele C) is an eQTL of <italic>LY75</italic> in the esophagus mucosa (NES=0.27) and of <italic>BAZ2B-AS</italic> in whole blood (NES=0.27), while rs2884110 (R<sup>2</sup>=0.85) is an eQTL of <italic>LY75</italic> in lung (NES=0.22). As for the chromosome 11, rs77599934 (allele G) is in moderate-to-strong LD (r<sup>2</sup>=0.776) with rs60606421 (G deletion, allele -) which is an eQTL associated with a reduced expression of <italic>DDIAS</italic> in the lungs (NES=-0.49, allele -). Associations with expression are shown in the supplementary Figure 4. The sentinel variant for the region in chromosome 16 is in perfect LD (<italic>r</italic><sup>2</sup>=1) with rs601183, an eQTL of <italic>ZNF774</italic> in the lung.</p>
<sec id="s2b1">
<title>Bayesian fine mapping</title>
<p>We performed different approaches to narrow down the prioritized loci to a set of most likely genes driving the associations. First, we computed credible sets at the 95% confidence level for causal variants and annotated them with VEP (and V2G aggregate scoring. The 95% confidence credible set from the region of chromosome 2 around rs13003835 included 76 variants, which can be found in the Supplementary Table 6 (VEP and V2G annotations are included in the Supplementary Tables 7 and 8). TheV2G score prioritized <italic>BAZ2B</italic> as the most likely gene driving the association. However, the approach was unable to converge allocating variants in a 95% confidence credible set for the region in chromosome 11.</p>
</sec>
<sec id="s2b2">
<title>Transcriptome-wide association study (TWAS)</title>
<p>Five novel genes, namely, <italic>SLC25A37, SMARCC1, CAMP, TYW3</italic>, and <italic>S100A12</italic> (supplementary Table 9), were found to be significantly associated in the cross-tissue TWAS. To our knowledge, these genes have not been reported previously in any COVID-19 TWAS or GWAS analyses published to date. In the single tissue analyses, <italic>ATP5O</italic> and <italic>CXCR6</italic> were significantly associated in the lungs, <italic>CCR9</italic> was significantly associated in whole blood, and <italic>IFNAR2</italic> and <italic>SLC25A37</italic> were associated in lymphocytes.</p>
<p>Likewise, we carried out TWAS analyses using the models trained in the admixed populations. However, no significant gene pairs were detected in this case. The top 10 genes with the lowest p-values for each of the datasets (Puerto-Ricans, Mexicans, African-Americans and pooled cohorts) are shown in the Supplementary Table 10. Although not significant, <italic>KCNC3</italic> was repeated in the four analyses, whereas <italic>MAPKAPK3, NAPSA</italic> and <italic>THAP5</italic> were repeated in 3 out of 4. Both <italic>NAPSA</italic> and <italic>KCNC3</italic> are located in the chromosome 19 and were reported in the latest HGI meta-analysis<sup><xref ref-type="bibr" rid="c19">19</xref></sup>.</p>
<p>All mapped genes from analyses conducted in AMR populations are shown in <xref rid="fig5" ref-type="fig">Figure 5</xref>.</p>
</sec>
</sec>
<sec id="s2c">
<title>Genetic architecture of COVID-19 hospitalization in AMR populations</title>
<sec id="s2c1">
<title>Allele frequencies of rs13003835 and rs77599934 across ancestries</title>
<p>Neither rs13003835 (<italic>BAZ2B</italic>) nor rs77599934 (<italic>DDIAS</italic>) were significantly associated in the COVID-19 HGI B2 cross-population or population-specific meta-analyses. Thus, we investigated their allele frequencies (AF) across populations and compared their effect sizes.</p>
<p>According to gnomAD v3.1.2, the T allele at rs13003835 (<italic>BAZ2B</italic>) has an AF of 43% in admixed AMR groups, while AF is lower in the EUR populations (16%) and in the global sample (29%). Local ancestry inference (LAI) reported by gnomAD shows that within the Native-American component, the risk allele T is the major allele, whereas it is the minor allele within the African and European LAI components. These large differences in AF might be the reason underlying the association found in AMR populations. However, when comparing effect sizes between populations, we found that they were in opposite directions between SAS-AMR and EUR-AFR-EAS and that there was large heterogeneity among them (<xref rid="fig3" ref-type="fig">Figure 3</xref>). We queried SNPs within 50kb windows of the lead variant in each of the other populations that had p-value&lt;0.01. The variant with the lowest p-value in the EUR population was rs559179177 (p=1.72×10<sup>−4</sup>), which is in perfect LD (r<sup>2</sup>=1) in the 1KGP EUR population with our sentinel variant (rs13003835), and in moderate LD r<sup>2</sup>=0.4 in AMR populations. Since this variant was absent from the AMR analysis, probably due to its low frequency, it could not be meta-analyzed. Power calculations revealed that the EUR analysis was underpowered for this variant to achieve genome-wide significance (77.6%, assuming an effect size of 0.46, EAF= 0.0027, and number of cases/controls as shown in the HGI website for B2-EUR). In the cross-population meta-analysis (B2-ALL), rs559179177 obtained a p-value of 5.9×10<sup>−4</sup>.</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Forest plot showing effect sizes and the corresponding confidence intervals for the sentinel variants identified in the AMR meta-analysis across populations.</title>
<p>All beta values with their corresponding CIs were retrieved from the B2 population-specific meta-analysis from the HGI v7 release, except for AMR, for which the beta value and IC from the HGI<sub>AMR</sub>-SCOURGE meta-analysis are represented.</p></caption>
<graphic xlink:href="23293871v4_fig3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>rs77599934 (<italic>DDIAS</italic>) had an AF of 1.1% for the G allele in the nonhospitalized controls (<xref rid="tbl2" ref-type="table">Table 2</xref>), in line with the recorded gnomAD AF of 1% in admixed AMR groups. This variant has the potential to be a population-specific variant, given the allele frequencies in other population groups, such as EUR (0% in Finnish, 0.025% in non-Finnish), EAS (0%) and SAS (0.042%), and its greater effect size over AFR populations (<xref rid="fig3" ref-type="fig">Figure 3</xref>). Examining the LAI, the G allele occurs at a 10.8% frequency in the African component, while it is almost absent in the Native-American and European. Due to its low MAF, rs77599934 was not analyzed in the COVID-19 HGI B2 cross-population meta-analysis and was only present in the HGI B2 AFR population-specific meta-analysis, precluding the comparison (<xref rid="fig3" ref-type="fig">Figure 3</xref>). For this reason, we retrieved the variant with the lowest p-value within a 50 kb region around rs77599934 in the COVID-19 HGI cross-population analysis to investigate whether it was in moderate-to-strong LD with our sentinel variant. The variant with the smallest p-value was rs75684040 (OR=1.07, 95% CI=1.03-1.12, p=1.84×10<sup>−3</sup>). However, LD calculations using the 1KGP phase 3 dataset indicated that rs77599934 and rs75684040 were poorly correlated (r<sup>2</sup>=0.11). As for AFR populations, the variant with the lowest p-value was rs138860115 (p=8.3×10<sup>−3</sup>), but it was not correlated with the lead SNP of this locus.</p>
</sec>
<sec id="s2c2">
<title>Cross-population meta-analyses</title>
<p>We carried out two cross-ancestry inverse variance-weighted fixed-effects meta-analyses with the admixed AMR GWAS meta-analysis results to evaluate whether the discovered risk loci replicated when considering other population groups. In doing so, we also identified novel cross-population COVID-19 hospitalization risk loci.</p>
<p>First, we combined the SCOURGE Latin American GWAS results with the HGI B2 ALL analysis (supplementary Table 11). We refer to this analysis as the SC-HGI<sub>ALL</sub> meta-analysis. Out of the 40 genome-wide significant loci associated with COVID-19 hospitalization in the last HGI release<sup><xref ref-type="bibr" rid="c1">1</xref></sup>, this study replicated 39, and the association was stronger than in the original study in 29 of those (supplementary Table 12). However, the variant rs13003835 located in <italic>BAZ2B</italic> did not replicate (OR=1.00, 95% CI=0.98-1.03, p=0.644).</p>
<p>In this cross-ancestry meta-analysis, we replicated two associations that were not found in HGIv7, albeit they were sentinel variants in the latest GenOMICC meta-analysis<sup><xref ref-type="bibr" rid="c2">2</xref></sup>. We found an association at the <italic>CASC20</italic> locus led by the variant rs2876034 (OR=0.95, 95% CI=0.93-0.97, p=2.83×10<sup>−8</sup>). This variant is in strong LD with the sentinel variant of that study (rs2326788, <italic>r</italic><sup>2</sup>=0.92), which was associated with critical COVID-19<sup>2</sup>. In addition, this meta-analysis identified the variant rs66833742 near <italic>ZBTB7A</italic> associated with COVID-19 hospitalization (OR=0.94, 95% CI=0.92-0.96, p=2.50×10<sup>−8</sup>). Notably, rs66833742 or its perfect proxy rs67602344 (r<sup>2</sup>=1) are also associated with upregulation of <italic>ZBTB7A</italic> in whole blood and in esophageal mucosa. This variant was previously associated with COVID-19 hospitalization<sup><xref ref-type="bibr" rid="c2">2</xref></sup>.</p>
<p>In a second analysis, we also explored the associations across the defined admixed AMR, EUR, and AFR ancestral sources by combining through meta-analysis the SCOURGE Latin American GWAS results with the HGI studies in EUR, AFR, and admixed AMR and excluding those from EAS and SAS (supplementary Table 13). We refer to this as the SC-HGI<sub>3POP</sub> meta-analysis. The association at rs13003835 (<italic>BAZ2B</italic>, OR=1.01, 95% CI=0.98-1.03, p=0.605) was not replicated, and rs77599934 near <italic>DDIAS</italic> could not be assessed, although the association at the <italic>ZBTB7A</italic> locus was confirmed (rs66833742, OR=0.94, 95% CI=0.92-0.96, p=1.89×10<sup>−8</sup>). The variant rs76564172 located near <italic>CREBBP</italic> also reached statistical significance (OR=1.31, 95% CI=1.25-1.38, p=9.64×10<sup>−9</sup>). The sentinel variant of the region linked to <italic>CREBBP</italic> (in the trans-ancestry meta-analysis) was also subjected a Bayesian fine mapping (supplementary Table 6). Eight variants were included in the credible set for the region in chromosome 16 (meta-analysis SC-HGI<sub>3POP</sub>).</p>
</sec>
</sec>
<sec id="s2d">
<title>Polygenic risk score models</title>
<p>Using the 49 variants associated with disease severity that are shared across populations according to the HGIv7, we constructed a polygenic risk score (PGS) model to assess its generalizability in the admixed AMR (supplementary Table 14). First, we calculated the PGS for the SCOURGE Latin Americans and explored the association with COVID-19 hospitalization under a logistic regression model. The PGS model was associated with a 1.48-fold increase in COVID-19 hospitalization risk per every PGS standard deviation. It also contributed to explaining a slightly larger variance (ΔR2=1.07%) than the baseline model. Subsequently, we divided the individuals into PGS deciles and percentiles to assess their risk stratification. The median percentile among controls was 40, while in cases, it was 63. Those in the top PGS decile exhibited a 2.89-fold (95% CI=2.37-3.54, p=1.29×10<sup>−7</sup>) greater risk compared to individuals in the deciles between 4 and 6 (corresponding to a score of the median distribution).</p>
<p>We also examined the distribution of PGS scores across a 5-level severity scale to further determine if there was any correspondence between clinical severity and genetic risk. Median PGS scores were lower in the asymptomatic and mild groups, whereas higher median scores were observed in the moderate, severe, and critical patients (<xref rid="fig4" ref-type="fig">Figure 4</xref>). We fitted a multinomial model using the asymptomatic class as a reference and calculated the OR for each category (supplementary Table 15), observing that the disease genetic risk was similar among asymptomatic, mild, and moderate patients. Given that the PGS was built with variants associated with critical disease and/or hospitalization and that the categories severe and critical correspond to hospitalized patients, these results underscore the ability of cross-ancestry PGS for risk stratification even in an admixed population.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4.</label>
<caption><title>(A) Polygenic risk stratified by PGS deciles comparing each risk group against the lowest risk group (OR-95% CI); (B) Distribution of the PGS scores in each of the severity scale classes.</title>
<p>0-Asymptomatic, 1-Mild disease, 2-Moderate disease, 3-Severe disease, 4-Critical disease.</p></caption>
<graphic xlink:href="23293871v4_fig4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Summary of the results from gene prioritization strategies used for genetic associations in AMR populations.</title>
<p>GWAS catalog association for <italic>BAZ2B-AS</italic> was with FEV/FCV ratio. Literature based evidence is further explored in discussion.</p></caption>
<graphic xlink:href="23293871v4_fig5.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>We have conducted the largest GWAS meta-analysis of COVID-19 hospitalization in admixed AMR to date. While the genetic risk basis discovered for COVID-19 is largely shared among populations, trans-ancestry meta-analyses on this disease have primarily included EUR samples. This dominance of GWAS in Europeans and the subsequent bias in sample sizes can mask population-specific genetic risks (i.e., variants that are monomorphic in some populations) or be less powered to detect risk variants having higher allele frequencies in population groups other than Europeans. In this sense, after combining data from admixed AMR patients, we found two risk loci that were first discovered in a GWAS of Latin American populations. Interestingly, the sentinel variant rs77599934 in the <italic>DDIAS</italic> gene is a rare coding variant (∼1% for allele G) with a large effect on COVID-19 hospitalization that is nearly monomorphic in most of the other populations. This has likely led to its exclusion from the cross-population meta-analyses conducted to date, remaining undetectable.</p>
<p>Fine mapping of the region harboring <italic>DDIAS</italic> did not reveal further information about which gene could be the more prone to be causal or about the functional consequences of the risk variant, but our sentinel variant was in strong LD with an eQTL that associated with reduced gene expression of <italic>DDIAS</italic> in the lung. <italic>DDIAS</italic>, known as damage-induced apoptosis suppressor gene, is itself a plausible candidate gene. It has been linked to DNA damage repair mechanisms: research has shown that depletion of <italic>DDIAS</italic> leads to an increase in ATM phosphorylation and the formation of p53-binding protein (53BP1) foci, a known biomarker of DNA double-strand breaks, suggesting a potential role in double-strand break repair<sup><xref ref-type="bibr" rid="c20">20</xref></sup>. Interestingly, a study found that infection by SARS-CoV-2 also triggered the phosphorylation of ATM kinase and inhibited repair mechanisms, causing the accumulation of DNA damage<sup><xref ref-type="bibr" rid="c21">21</xref></sup>. This gene has also been proposed as a potential biomarker for lung cancer after finding that it interacts with STAT3 in lung cancer cells, regulating IL-6<sup><xref ref-type="bibr" rid="c22">22</xref>,<xref ref-type="bibr" rid="c23">23</xref></sup> and thus mediating inflammatory processes, while another study determined that its blockade inhibited lung cancer cell growth<sup><xref ref-type="bibr" rid="c24">24</xref></sup>.Another prioritized gene from this region was <italic>PRCP</italic>, an angiotensinase which shares substrate specificity with ACE2 receptor. It has been positively linked to hypertension and some studies have raised hypotheses on its role in COVID-19 progression, particularly in relation to the development of pro-thrombotic events <sup><xref ref-type="bibr" rid="c25">25</xref>,<xref ref-type="bibr" rid="c26">26</xref></sup>.</p>
<p>The risk region found in chromosome 2 harbors more than one gene. The lead variant rs13003835 is located within <italic>BAZ2B</italic>, and it increases the expression of the antisense <italic>BAZ2B</italic> gene in whole blood. <italic>BAZ2B</italic> encodes one of the regulatory subunits of the Imitation switch (ISWI) chromatin remodelers<sup><xref ref-type="bibr" rid="c27">27</xref></sup> constituting the BRF-1/BRF-5 complexes with SMARCA1 and SMARCA5, respectively. Interestingly, it was discovered that <italic>lnc-BAZ2B</italic> promotes macrophage activation through regulation of <italic>BAZ2B</italic> expression. Its over-expression resulted in pulmonary inflammation and elevated levels of <italic>MUC5AC</italic> in mice with asthma<sup><xref ref-type="bibr" rid="c28">28</xref></sup>. This variant was also an eQTL for <italic>LY75</italic> (encoding lymphocyte antigen 75) in the esophageal mucosa tissue. Lymphocyte antigen 75 is involved in immune processes through antigen presentation in dendritic cells and endocytosis<sup><xref ref-type="bibr" rid="c29">29</xref></sup> and has been associated with inflammatory diseases, representing a compelling candidate for the region. Increased expression of <italic>LY75</italic> has been detected within hours after infection by SARS-CoV-2<sup><xref ref-type="bibr" rid="c30">30</xref>,<xref ref-type="bibr" rid="c31">31</xref></sup>. It is worth noting that differences in AF for this variant suggest that analyses in AMR populations might be more powered to detect the association, supporting the necessity of population-specific studies.</p>
<p>A third novel risk region was observed on chromosome 15 between the <italic>IQGAP1</italic> and <italic>ZNF774 genes</italic>, although it did not reach genome-wide significance.</p>
<p>Secondary analyses revealed five TWAS-associated genes, some of which have already been linked to severe COVID-19. In a comprehensive multitissue gene expression profiling study<sup><xref ref-type="bibr" rid="c32">32</xref></sup>, decreased expression of <italic>CAMP</italic> and <italic>S100A8</italic>/<italic>S100A9</italic> genes in patients with severe COVID-19 was observed, while another study detected the upregulation of <italic>SCL25A37</italic> among patients with severe COVID-19<sup><xref ref-type="bibr" rid="c33">33</xref></sup>. <italic>SMARCC1</italic> is a subunit of the SWI/SNF chromatin remodeling complex that has been identified as proviral for SARS-CoV-2 and other coronavirus strains through a genome-wide screen<sup><xref ref-type="bibr" rid="c34">34</xref></sup>. This complex is crucial for <italic>ACE2</italic> expression and viral entry into the cell<sup><xref ref-type="bibr" rid="c35">35</xref></sup>. However, it should be noted that using eQTL mostly from European populations such as those in GTEx could result in reduced power to detect associations.</p>
<p>To explore the genetic architecture of the trait among admixed AMR populations, we performed two cross-ancestry meta-analyses including the SCOURGE Latin American cohort GWAS findings. We found that the two novel risk variants were not associated with COVID-19 hospitalization outside the population-specific meta-analysis, highlighting the importance of complementing trans-ancestry meta-analyses with group-specific analyses. Notably, this analysis did not replicate the association at the <italic>DSTYK</italic> locus, which was associated with severe COVID-19 in Brazilian individuals with higher European admixture<sup><xref ref-type="bibr" rid="c36">36</xref></sup>. This lack of replication aligns with the initial hypothesis of that study suggesting that the risk haplotype was derived from European populations, as we reduced the weight of this ancestral contribution in our study by excluding those individuals.</p>
<p>Moreover, these cross-ancestry meta-analyses pointed to three loci that were not genome-wide significant in the HGIv7 ALL meta-analysis: a novel locus at <italic>CREBBP</italic> and two loci at <italic>ZBTB7A</italic> and <italic>CASC20</italic> that were reported in another meta-analysis. <italic>CREBBP</italic> and <italic>ZBTB7A</italic> achieved a stronger significance when considering only the EUR, AFR, and admixed AMR GIA groups. According to a recent study, elevated levels of the <italic>ZBTB7A</italic> gene promote a quasihomeostatic state between coronaviruses and host cells, preventing cell death by regulating oxidative stress pathways<sup><xref ref-type="bibr" rid="c37">37</xref></sup>. This gene is involved in several signaling pathways, such as B and T-cell differentiation<sup><xref ref-type="bibr" rid="c38">38</xref></sup>. On a separate note, <italic>CREBBP</italic> encodes the CREB binding protein (CBP), which is involved in transcriptional activation and is known to positively regulate the type I interferon response through virus-induced phosphorylation of IRF-3<sup><xref ref-type="bibr" rid="c39">39</xref></sup>. In addition, the CREBP/CBP interaction has been implicated in SARS-CoV-2 infection<sup><xref ref-type="bibr" rid="c40">40</xref></sup> via the cAMP/PKA pathway. In fact, cells with suppressed <italic>CREBBP</italic> gene expression exhibit reduced replication of the so-called Delta and Omicron SARS-CoV-2 variants<sup><xref ref-type="bibr" rid="c40">40</xref></sup>.</p>
<p>We developed a cross-population PGS model, which effectively stratified individuals based on their genetic risk and demonstrated consistency with the clinical severity classification of the patients. Only a few polygenic scores were derived from COVID-19 GWAS data. Horowitz et al. (2022)<sup><xref ref-type="bibr" rid="c41">41</xref></sup> developed a score using 6 and 12 associated variants (PGS ID: PGP000302) and reported an associated OR (top 10% vs rest) of 1.38 for risk of hospitalization in European populations, whereas the OR for Latin-American populations was 1.56. Since their sample size and the number of variants included in the PGS were lower, direct comparisons are not straightforward. Nevertheless, our analysis provides the first results for a PRS applied to a relatively large AMR cohort, being of value for future analyses regarding PRS transferability.</p>
<p>This study is subject to limitations, mostly concerning sample recruitment and composition. The SCOURGE Latino-American sample size is small, and the GWAS is likely underpowered. Another limitation is the difference in case–control recruitment across sampling regions that, yet controlled for, may reduce the ability to observe significant associations driven by different compositions of the populations. In this sense, the identified risk loci might not replicate in a cohort lacking any of the parental population sources from the three-way admixture. Likewise, we could not explicitly control for socioenvironmental factors that could have affected COVID-19 spread and hospitalization rates, although genetic principal components are known to capture nongenetic factors. Finally, we must acknowledge the lack of a replication cohort. We used all the available GWAS data for COVID-19 hospitalization in admixed AMR in this meta-analysis due to the low number of studies conducted. Therefore, we had no studies to replicate or validate the results. These concerns may be addressed in the future by including more AMR GWAS in the meta-analysis, both by involving diverse populations in study designs and by supporting research from countries in Latin America.</p>
<p>This study provides novel insights into the genetic basis of COVID-19 severity, emphasizing the importance of considering host genetic factors by using non-European populations, especially of admixed sources. Such complementary efforts can pin down new variants and increase our knowledge on the host genetic factors of severe COVID-19.</p>
</sec>
<sec id="s4">
<title>Materials and methods</title>
<sec id="s4a">
<title>GWAS in Latin Americans from SCOURGE</title>
<sec id="s4a1">
<title>The SCOURGE Latin American cohort</title>
<p>A total of 3,729 COVID-19-positive cases were recruited across five countries from Latin America (Mexico, Brazil, Colombia, Paraguay, and Ecuador) by 13 participating centers (supplementary Table 1) from March 2020 to July 2021. In addition, we included 1,082 COVID-19-positive individuals recruited between March and December 2020 in Spain who either had evidence of origin from a Latin American country or showed inferred genetic admixture between AMR, EUR, and AFR (with &lt; 0.05% SAS/EAS). These individuals were excluded from a previous SCOURGE study that focused on participants with European genetic ancestries<sup><xref ref-type="bibr" rid="c16">16</xref></sup>. We used hospitalization as a proxy for disease severity and defined COVID-19-positive patients who underwent hospitalization as a consequence of the infection as cases and those who did not need hospitalization due to COVID-19 as controls.</p>
<p>Samples and data were collected with informed consent after the approval of the Ethics and Scientific Committees from the participating centers and by the Galician Ethics Committee Ref 2020/197. Recruitment of patients from IMSS (in Mexico, City) was approved by the National Committee of Clinical Research from Instituto Mexicano del Seguro Social, Mexico (protocol R-2020-785-082).</p>
<p>Samples and data were processed following normalized procedures. The REDCap electronic data capture tool<sup><xref ref-type="bibr" rid="c42">42</xref>,<xref ref-type="bibr" rid="c43">43</xref></sup>, hosted at Centro de Investigación Biomédica en Red (CIBER) from the Instituto de Salud Carlos III (ISCIII), was used to collect and manage demographic, epidemiological, and clinical variables. Subjects were diagnosed with COVID-19 based on quantitative PCR tests (79.3%) or according to clinical (2.2%) or laboratory procedures (antibody tests: 16.3%; other microbiological tests: 2.2%).</p>
</sec>
<sec id="s4a2">
<title>SNP array genotyping</title>
<p>Genomic DNA was obtained from peripheral blood and isolated using the Chemagic DNA Blood 100 kit (PerkinElmer Chemagen Technologies GmbH), following the manufacturer’s recommendations.</p>
<p>Samples were genotyped with the Axiom Spain Biobank Array (Thermo Fisher Scientific) following the manufacturer’s instructions in the Santiago de Compostela Node of the National Genotyping Center (CeGen-ISCIII; <ext-link ext-link-type="uri" xlink:href="http://www.usc.es/cegen">http://www.usc.es/cegen</ext-link>). This array contains probes for genotyping a total of 757,836 SNPs. Clustering and genotype calling were performed using Axiom Analysis Suite v4.0.3.3 software.</p>
</sec>
<sec id="s4a3">
<title>Quality control steps and variant imputation</title>
<p>A quality control (QC) procedure using PLINK 1.9<sup><xref ref-type="bibr" rid="c44">44</xref></sup> was applied to both samples and the genotyped SNPs. We excluded variants with a minor allele frequency (MAF) &lt;1%, a call rate &lt;98%, and markers strongly deviating from Hardy-Weinberg equilibrium expectations (<italic>p</italic>&lt;1×10<sup>−6</sup>) with mid-p adjustment. We also explored the excess of heterozygosity to discard potential cross-sample contamination. Samples missing &gt;2% of the variants were filtered out. Subsequently, we kept the autosomal SNPs, removed high-LD regions and conducted LD pruning (windows of 1,000 SNPs, with a step size of 80 and a r<sup>2</sup> threshold of 0.1) to assess kinship and estimate the global ancestral proportions. Kinship was evaluated based on IBD values, removing one individual from each pair with PI_HAT&gt;0.25 that showed a Z0, Z1, and Z2 coherent pattern (according to the theoretical expected values for each relatedness level). Genetic principal components (PCs) were calculated with PLINK with the subset of LD pruned variants.</p>
<p>Genotypes were imputed with the TOPMed version r2 reference panel (GRCh38) using the TOPMed Imputation Server, and variants with Rsq&lt;0.3 or with MAF&lt;1% were filtered out. A total of 4,348 individuals and 10,671,028 genetic variants were included in the analyses.</p>
</sec>
<sec id="s4a4">
<title>Genetic admixture estimation</title>
<p>Global genetic inferred ancestry (GIA), referred to the genetic similarity to the used reference individuals, was estimated with ADMIXTURE<sup><xref ref-type="bibr" rid="c45">45</xref></sup> v1.3 software following a two-step procedure. First, we randomly sampled 79 European (EUR) and 79 African (AFR) samples from The 1000 Genomes Project (1KGP)<sup><xref ref-type="bibr" rid="c46">46</xref></sup> and merged them with the 79 Native American (AMR) samples from Mao <italic>et al</italic>.<sup><xref ref-type="bibr" rid="c47">47</xref></sup> keeping the biallelic SNPs. LD-pruned variants were selected from this merge using the same parameters as in the QC. We then run an unsupervised analysis with K=3 to redefine and homogenize the clusters and to compose a refined reference for the analyses by applying a threshold of ≥95% of belonging to a particular cluster. As a result, 20 AFR, 18 EUR, and 38 AMR individuals were removed. The same LD-pruned variants data from the remaining individuals were merged with the SCOURGE Latin American cohort to perform supervised clustering and estimate admixture proportions. A total of 471 samples from the SCOURGE cohort with &gt;80% estimated European GIA were removed to reduce the weight of the European ancestral component, leaving a total of 3,512 admixed Latin American (AMR) subjects for downstream analyses.</p>
</sec>
<sec id="s4a5">
<title>Association analysis</title>
<p>The results for the SCOURGE Latin American GWAS were obtained by testing for COVID-19 hospitalization as a surrogate of severity. To accommodate the continuum of GIA in the cohort, we opted for a joint testing of all the individuals as a single study using a mixed regression model, as this approach has demonstrated a greater power and sufficient control of population structure<sup><xref ref-type="bibr" rid="c48">48</xref></sup>. The SCOURGE cohort consisted of 3,512 COVID-19-positive patients: cases (n=1,625) were defined as hospitalized COVID-19 patients, and controls (n=1,887) were defined as nonhospitalized COVID-19-positive patients.</p>
<p>Logistic mixed regression models were fitted using the SAIGEgds<sup><xref ref-type="bibr" rid="c49">49</xref></sup> package in R, which implements the two-step mixed SAIGE<sup><xref ref-type="bibr" rid="c50">50</xref></sup> model methodology and the SPA test. Baseline covariables included sex, age (continuous), and the first 10 PCs. To account for potential heterogeneity in the recruitment and hospitalization criteria across the participating countries, we adjusted the models by groups of the recruitment areas classified into six categories: Brazil, Colombia, Ecuador, Mexico, Paraguay, and Spain. This dataset has not been used in any previously published GWAS of COVID-19.</p>
</sec>
</sec>
<sec id="s4b">
<title>Meta-analysis of Latin American populations</title>
<p>The results of the SCOURGE Latin American cohort were meta-analyzed with the AMR HGI-B2 data, conforming our primary analysis. Summary results from the HGI freeze 7 B2 analysis corresponding to the admixed AMR population were obtained from the public repository (April 8, 2022: <ext-link ext-link-type="uri" xlink:href="https://www.covid19hg.org/results/r7/">https://www.covid19hg.org/results/r7/</ext-link>), summing up 3,077 cases and 66,686 controls from seven contributing studies. We selected the B2 phenotype definition because it offered more power, and the presence of population controls not ascertained for COVID-19 does not have a drastic impact on the association results.</p>
<p>The meta-analysis was performed using an inverse-variance weighting method in METAL<sup><xref ref-type="bibr" rid="c51">51</xref></sup>. The average allele frequency was calculated, and variants with low imputation quality (Rsq&lt;0.3) were filtered out, leaving 10,121,172 variants for meta-analysis.</p>
<p>Heterogeneity between studies was evaluated with Cochran’s Q test. The inflation of results was assessed based on a genomic control (lambda).</p>
<sec id="s4b1">
<title>Replicability of associations</title>
<p>The model-based method MAMBA<sup><xref ref-type="bibr" rid="c52">52</xref></sup> was used to calculate the posterior probabilities of replication for each of the lead variants. Variants with p&lt;1×10<sup>−05</sup> were clumped and combined with random pruned variants from the 1KGP AMR reference panel. Then, MAMBA was applied to the set of significant and non-significant variants.</p>
<p>Each of the lead variants was also tested for association with the main comorbidities in the SCOURGE cohort with logistic regression models (adjusted by the same base covariables as the GWAS).</p>
</sec>
</sec>
<sec id="s4c">
<title>Definition of the genetic risk loci and putative functional impact</title>
<sec id="s4c1">
<title>Definition of lead variant and novel loci</title>
<p>To define the lead variants in the loci that were genome-wide significant, LD-clumping was performed on the meta-analysis data using a threshold p-value&lt;5×10<sup>−8</sup>, clump distance=1500 kb, independence set at a threshold r<sup>2</sup>=0.1 and the SCOURGE cohort genotype data as the LD reference panel. Independent loci were deemed as a novel finding if they met the following criteria: 1) p-value&lt;5×10<sup>−8</sup> in the meta-analysis and p-value&gt;5×10<sup>−8</sup> in the HGI B2 ALL meta-analysis or in the HGI B2 AMR and AFR and EUR analyses when considered separately; 2) Cochran’s Q-test for heterogeneity of effects is &lt;0.05/N<sub>loci</sub>, where N<sub>loci</sub> is the number of independent variants with p&lt;5×10<sup>−8</sup>; and 3) the nearest gene has not been previously described in the latest HGIv7 update.</p>
</sec>
<sec id="s4c2">
<title>Annotation and initial mapping</title>
<p>Functional annotation was performed with FUMA<sup><xref ref-type="bibr" rid="c53">53</xref></sup> for those variants with a p-value&lt;5×10<sup>−8</sup> or in moderate-to-strong LD (r<sup>2</sup>&gt;0.6) with the lead variants, where the LD was calculated from the 1KGP AMR panel. Genetic risk loci were defined by collapsing LD blocks within 250 kb. Then, genes, scaled CADD v1.4 scores, and RegulomeDB v1.1 scores were annotated for the resulting variants with ANNOVAR in FUMA<sup><xref ref-type="bibr" rid="c53">53</xref></sup>. Gene-based analysis was also performed using MAGMA<sup><xref ref-type="bibr" rid="c54">54</xref></sup> as implemented in FUMA under the SNP-wide mean model using the 1KGP AMR reference panel. Significance was set at a threshold p&lt;2.66×10<sup>−6</sup> (which assumes that variants can be mapped to a total of 18,817 genes).</p>
<p>FUMA allowed us to perform initial gene mapping by two approaches: (1) positional mapping, which assigns variants to genes by physical distance using 10-kb windows; and (2) eQTL mapping based on GTEx v.8 data from whole blood, lungs, lymphocytes, and esophageal mucosa tissues, establishing a false discovery rate (FDR) of 0.05 to declare significance for variant-gene pairs.</p>
<p>Subsequently, to assign the variants to the most likely gene driving the association, we refined the candidate genes by fine mapping the discovered regions</p>
</sec>
<sec id="s4c3">
<title>Bayesian fine-mapping</title>
<p>To conduct a Bayesian fine mapping, credible sets for the genetic loci considered novel findings were calculated on the results from each of the three meta-analyses to identify a subset of variants most likely containing the causal variant at the 95% confidence level, assuming that there is a single causal variant and that it has been tested. We used <italic>corrcoverage</italic> (<ext-link ext-link-type="uri" xlink:href="https://cran.rstudio.com/web/packages/corrcoverage/index.html">https://cran.rstudio.com/web/packages/corrcoverage/index.html</ext-link>) for R to calculate the posterior probabilities of the variant being causal for all variants with a r<sup>2</sup>&gt;0.1 with the leading SNP and within 1 Mb except for the novel variant in chromosome 19, for which we used a window of 0.5 Mb. Variants were added to the credible set until the sum of the posterior probabilities was ≥0.95.</p>
</sec>
<sec id="s4c4">
<title>VEP and V2G annotation</title>
<p>We used the Variant-to-Gene (V2G) score to prioritize the genes that were most likely affected by the functional evidence based on expression quantitative trait loci (eQTL), chromatin interactions, in silico functional predictions, and distance between the prioritized variants and transcription start site (TSS), based on data from the Open Targets Genetics portal<sup><xref ref-type="bibr" rid="c55">55</xref></sup>. Details of the data integration and the weighting of each of the datasets are described with detail here: <ext-link ext-link-type="uri" xlink:href="https://genetics-docs.opentargets.org/our-approach/data-pipeline">https://genetics-docs.opentargets.org/our-approach/data-pipeline</ext-link>. V2G is a score for ranking the functional genomics evidence that supports the connection between variants and genes (the higher the score the more likely the variant to be functionally implicated on the assigned gene). We used VEP release 111 (URL: <ext-link ext-link-type="uri" xlink:href="https://www.ensembl.org/info/docs/tools/vep/index.html">https://www.ensembl.org/info/docs/tools/vep/index.html</ext-link>; accessed April 10, 2024) <sup><xref ref-type="bibr" rid="c56">56</xref></sup> to annotate the following: gene symbol, function (exonic, intronic, intergenic, non-coding RNA, etc.), impact, feature type, feature, and biotype.</p>
<p>We queried the GWAS Catalog (date of accession: 01/07/2024) for evidence of association of each of the prioritized genes with traits related to lung diseases or phenotypes. Lastly, those which were linked to COVID-19, infection, or lung diseases in the revised literature were classified as “literature evidence”.</p>
</sec>
</sec>
<sec id="s4d">
<title>Transcription-wide association studies</title>
<p>Transcriptome-wide association studies (TWAS) were conducted using the pretrained prediction models with MASHR-computed effect sizes on GTEx v8 datasets<sup><xref ref-type="bibr" rid="c57">57</xref>,<xref ref-type="bibr" rid="c58">58</xref></sup>. The results from the Latin American meta-analysis were harmonized and integrated with the prediction models through S-PrediXcan<sup><xref ref-type="bibr" rid="c59">59</xref></sup> for lung, whole blood, lymphocyte and esophageal mucosal tissues. Statistical significance was set at p-value&lt;0.05 divided by the number of genes that were tested for each tissue. Subsequently, we leveraged results for all 49 tissues and ran a multitissue TWAS to improve the power for association, as demonstrated recently<sup><xref ref-type="bibr" rid="c60">60</xref></sup>. TWAS was also performed using recently published gene expression datasets derived from a cohort of African Americans, Puerto Ricans, and Mexican Americans (GALA II-SAGE)<sup><xref ref-type="bibr" rid="c61">61</xref></sup>.</p>
</sec>
<sec id="s4e">
<title>Cross-population meta-analyses</title>
<p>We conducted two additional meta-analyses to investigate the ability of combining populations to replicate our discovered risk loci. This methodology enabled the comparison of effects and the significance of associations in the novel risk loci between the results from analyses that included or excluded other population groups.</p>
<p>The first meta-analysis comprised the five populations analyzed within HGI (B2-ALL). Additionally, to evaluate the three GIA components within the SCOURGE Latin American cohort<sup><xref ref-type="bibr" rid="c62">62</xref></sup>, we conducted a meta-analysis of the admixed AMR, EUR, and AFR cohorts (B2). All summary statistics were retrieved from the HGI repository. We applied the same meta-analysis methodology and filters as in the admixed AMR meta-analysis.</p>
</sec>
<sec id="s4f">
<title>Cross-population Polygenic Risk Score</title>
<p>A polygenic risk score (PGS) for critical COVID-19 was derived by combining the variants associated with hospitalization or disease severity that have been discovered to date. We curated a list of lead variants that were 1) associated with either severe disease or hospitalization in the latest HGIv7 release<sup><xref ref-type="bibr" rid="c1">1</xref></sup> (using the hospitalization weights) or 2) associated with severe disease in the latest GenOMICC meta-analysis<sup><xref ref-type="bibr" rid="c2">2</xref></sup> that were not reported in the latest HGI release. A total of 48 markers were used in the PGS model (see supplementary Table 13) since two variants were absent from our study.</p>
<p>Scores were calculated and normalized for the SCOURGE Latin American cohort with PLINK 1.9. This cross-ancestry PGS was used as a predictor for hospitalization (COVID-19-positive patients who were hospitalized <italic>vs</italic>. COVID-19-positive patients who did not necessitate hospital admission) by fitting a logistic regression model. Prediction accuracy for the PGS was assessed by performing 500 bootstrap resamples of the increase in the pseudo-R-squared. We also divided the sample into deciles and percentiles to assess risk stratification. The models were fit for the dependent variable adjusting for sex, age, the first 10 PCs, and the sampling region (in the Admixed AMR cohort) with and without the PGS, and the partial pseudo-R2 was computed and averaged among the resamples.</p>
<p>A clinical severity scale was used in a multinomial regression model to further evaluate the power of this cross-ancestry PGS for risk stratification. These severity strata were defined as follows: 0) asymptomatic; 1) mild, that is, with symptoms, but without pulmonary infiltrates or need of oxygen therapy; 2) moderate, that is, with pulmonary infiltrates affecting &lt;50% of the lungs or need of supplemental oxygen therapy; 3) severe disease, that is, with hospital admission and PaO<sub>2</sub>&lt;65 mmHg or SaO<sub>2</sub>&lt;90%, PaO<sub>2</sub>/FiO<sub>2</sub>&lt;300, SaO<sub>2</sub>/FiO<sub>2</sub>&lt;440, dyspnea, respiratory frequency≥22 bpm, and infiltrates affecting &gt;50% of the lungs; and 4) critical disease, that is, with an admission to the ICU or need of mechanical ventilation (invasive or noninvasive).</p>
</sec>
</sec>
</body>
<back>
<sec id="s5" sec-type="data-availability">
<title>Data availability</title>
<p>Summary statistics from the SCOURGE Latin American GWAS and the analysis scripts are available from the public repository <ext-link ext-link-type="uri" xlink:href="https://github.com/CIBERER/Scourge-COVID19">https://github.com/CIBERER/Scourge-COVID19</ext-link>.</p>
</sec>
<sec id="s6">
<title>Funding</title>
<p>Instituto de Salud Carlos III (COV20_00622 to A.C., COV20/00792 to M.B., COV20_00181 to C.A., COV20_1144 to M.A.J.S. and A.F.R., PI20/00876 to C.F.); European Union (ERDF) ‘A way of making Europe’. Fundación Amancio Ortega, Banco de Santander (to A.C.), Estrella de Levante S.A. and Colabora Mujer Association (to E.G.-N.) and Obra Social La Caixa (to R.B.); Agencia Estatal de Investigación (RTC-2017-6471-1 to C.F.), Cabildo Insular de Tenerife (CGIEU0000219140 ‘Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19’ to C.F.) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57 to C.F.). SD-DA was supported by a Xunta de Galicia predoctoral fellowship.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>Study design: RC, AC, CF. Data collection: SCOURGE cohort group. Data analysis: SD-DA, RC, ADL, CF, JML-S. Interpretation: SD-DA, RC, ADL. Drafting of the manuscript: SD-DA, RC, ADL, CF, AR-M, AC. Critical revision of the manuscript: SD-DA, RC, ADL, AC, CF, JAR, AR-M, and PL. Approval of the final version of the publication: all coauthors.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>The contribution of the Centro National de Genotipado (CEGEN) and Centro de Supercomputación de Galicia (CESGA) for funding this project by providing supercomputing infrastructures is also acknowledged. The authors are also particularly grateful for the supply of material and the collaboration of patients, health professionals from participating centers and biobanks. Namely, Biobanc-Mur, and biobancs of the Complexo Hospitalario Universitario de A Coruña, Complexo Hospitalario Universitario de Santiago, Hospital Clínico San Carlos, Hospital La Fe, Hospital Universitario Puerta de Hierro Majadahonda—Instituto de Investigación Sanitaria Puerta de Hierro—Segovia de Arana, Hospital Ramón y Cajal, IDIBGI, IdISBa, IIS Biocruces Bizkaia, IIS Galicia Sur. Also biobanks of the Sistema de Salud de Aragón, Sistema Sanitario Público de Andalucía, and Banco Nacional de ADN.</p>
</ack>
<sec id="d1e3639" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="d1e4325">
<label>Supplementary Material</label>
<media xlink:href="supplements/293871_file02.docx"/>
</supplementary-material>
<supplementary-material id="d1e4332">
<label>Supplementary Tables</label>
<media xlink:href="supplements/293871_file03.xlsx"/>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><collab>The COVID-19 Host Genetics Initiative</collab>. &amp; <string-name><surname>Ganna</surname>, <given-names>A.</given-names></string-name></person-group> <article-title>A second update on mapping the human genetic architecture of COVID-19</article-title> <source>medRxiv</source>. <elocation-id>2022.12.24.22283874</elocation-id> <pub-id pub-id-type="doi">10.1101/2022.12.24.22283874</pub-id> (<year>2023</year>).</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pairo-Castineira</surname>, <given-names>E.</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19</article-title> <source>Nature</source>. <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41586-023-06034-3">https://www.nature.com/articles/s41586-023-06034-3</ext-link>. <year>2023</year></mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Niemi</surname>, <given-names>M. E. K.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Mapping the human genetic architecture of COVID-19</article-title>. <source>Nature</source> <volume>600</volume>, <fpage>472</fpage>–<lpage>477</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Popejoy</surname>, <given-names>A. B.</given-names></string-name> &amp; <string-name><surname>Fullerton</surname>, <given-names>S. M.</given-names></string-name></person-group> <article-title>Genomics is failing on diversity</article-title>. <source>Nature</source> <volume>538</volume>, <fpage>161</fpage>–<lpage>164</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sirugo</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Williams</surname>, <given-names>S. M.</given-names></string-name> &amp; <string-name><surname>Tishkoff</surname>, <given-names>S. A.</given-names></string-name></person-group> <article-title>The Missing Diversity in Human Genetic Studies</article-title>. <source>Cell</source> <volume>177</volume>, <fpage>26</fpage>–<lpage>31</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>Y. R.</given-names></string-name> &amp; <string-name><surname>Keating</surname>, <given-names>B. J.</given-names></string-name></person-group> <article-title>Trans-ethnic genome-wide association studies: advantages and challenges of mapping in diverse populations</article-title>. <source>Genome Med</source>. <volume>6</volume>, <fpage>91</fpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosenberg</surname>, <given-names>N. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Genome-wide association studies in diverse populations</article-title>. <source>Nat. Rev. Genet</source>. <volume>11</volume>, <fpage>356</fpage>–<lpage>366</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kwok</surname>, <given-names>A. J.</given-names></string-name>, <string-name><surname>Mentzer</surname>, <given-names>A.</given-names></string-name> &amp; <string-name><surname>Knight</surname>, <given-names>J. C.</given-names></string-name></person-group> <article-title>Host genetics and infectious disease: new tools, insights and translational opportunities</article-title>. <source>Nat. Rev. Genet</source>. <volume>22</volume>, <fpage>137</fpage>–<lpage>153</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karlsson</surname>, <given-names>E. K.</given-names></string-name>, <string-name><surname>Kwiatkowski</surname>, <given-names>D. P.</given-names></string-name> &amp; <string-name><surname>Sabeti</surname>, <given-names>P. C.</given-names></string-name></person-group> <article-title>Natural selection and infectious disease in human populations</article-title>. <source>Nat. Rev. Genet</source>. <volume>15</volume>, <fpage>379</fpage>–<lpage>393</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Namkoong</surname>, <given-names>H.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>DOCK2 is involved in the host genetics and biology of severe COVID-19</article-title>. <source>Nature</source> <volume>609</volume>, <fpage>754</fpage>–<lpage>760</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bastard</surname>, <given-names>P.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes</article-title>. <source>J. Exp. Med</source>. <volume>219</volume>, <fpage>e20220028</fpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Duncan</surname>, <given-names>C. J. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic</article-title>. <source>J. Exp. Med</source>. <volume>219</volume>, <fpage>e20212427</fpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peterson</surname>, <given-names>R. E.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Genome-wide Association Studies in Ancestrally Diverse Populations: Opportunities, Methods, Pitfalls, and Recommendations</article-title>. <source>Cell</source> <volume>179</volume>, <fpage>589</fpage>–<lpage>603</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Mester</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Impact of cross-ancestry genetic architecture on GWAS in admixed populations</article-title>. <source>bioRxiv</source> <elocation-id>2023.01.20.524946</elocation-id> <pub-id pub-id-type="doi">10.1101/2023.01.20.524946</pub-id> (<year>2023</year>).</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="web"><person-group person-group-type="author"><string-name><surname>Atkinson</surname> <given-names>E.G.</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and to boost power</article-title> <source>Nature Genetics</source>. <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41588-020-00766-y">https://www.nature.com/articles/s41588-020-00766-y</ext-link>. <year>2021</year></mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cruz</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Novel genes and sex differences in COVID-19 severity</article-title>. <source>Hum. Mol. Genet</source>. <volume>31</volume>, <fpage>3789</fpage>–<lpage>3806</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Degenhardt</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Detailed stratified GWAS analysis for severe COVID-19 in four European populations</article-title>. <source>Hum. Mol. Genet</source>. <volume>31</volume>, <fpage>3945</fpage>–<lpage>3966</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kousathanas</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Whole-genome sequencing reveals host factors underlying critical COVID-19</article-title> <source>Nature</source>. <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41586-022-04576-6">https://www.nature.com/articles/s41586-022-04576-6</ext-link>. <year>2022</year></mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanai</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>A second update on mapping the human genetic architecture of COVID-19</article-title>. <source>Nature</source> <volume>621</volume>, <fpage>E7</fpage>–<lpage>E26</lpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brunette</surname>, <given-names>G.J.</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Evolution-based screening enables genome-wide prioritization and discovery of DNA repair genes |</article-title> <source>PNAS</source>. <ext-link ext-link-type="uri" xlink:href="https://www.pnas.org/doi/full/10.1073/pnas.1906559116">https://www.pnas.org/doi/full/10.1073/pnas.1906559116</ext-link>. <year>2019</year></mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gioia</surname>, <given-names>U.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>SARS-CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 recruitment, and cellular senescence</article-title>. <source>Nat. Cell Biol</source>. <volume>25</volume>, <fpage>550</fpage>–<lpage>564</lpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Im</surname>, <given-names>J.-Y.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>DDIAS promotes STAT3 activation by preventing STAT3 recruitment to PTPRM in lung cancer cells</article-title>. <source>Oncogenesis</source> <volume>9</volume>, <fpage>1</fpage>–<lpage>11</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Im</surname>, <given-names>J.-Y.</given-names></string-name>, <string-name><surname>Kang</surname>, <given-names>M.-J.</given-names></string-name><string-name><surname>Kim</surname>, <given-names>B.-K.</given-names></string-name> &amp; <string-name><surname>Won</surname>, <given-names>M.</given-names></string-name></person-group> <article-title>DDIAS, DNA damage-induced apoptosis suppressor, is a potential therapeutic target in cancer</article-title>. <source>Exp. Mol. Med</source>. <fpage>1</fpage>–<lpage>7</lpage> (<year>2023</year>) doi:<pub-id pub-id-type="doi">10.1038/s12276-023-00974-6</pub-id>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Won</surname>, <given-names>K-J.</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Human Noxin is an anti-apoptotic protein in response to DNA damage of A549 non-small cell lung carcinoma</article-title> <source>International Journal of Cancer - Wiley Online Library</source>. <ext-link ext-link-type="uri" xlink:href="https://onlinelibrary.wiley.com/doi/10.1002/ijc.28600">https://onlinelibrary.wiley.com/doi/10.1002/ijc.28600</ext-link>. <year>2014</year></mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Angeli</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure</article-title>. <source>Eur. J. Intern. Med</source>. <volume>109</volume>, <fpage>12</fpage>–<lpage>21</lpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Silva-Aguiar</surname>, <given-names>R. P.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients</article-title>. <source>Am. J. Physiol.-Lung Cell. Mol. Physiol</source>. <volume>319</volume>, <fpage>L596</fpage>–<lpage>L602</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The emerging role of ISWI chromatin remodeling complexes in cancer</article-title>. <source>J. Exp. Clin. Cancer Res</source>. <volume>40</volume>, <fpage>346</fpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xia</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>lnc-BAZ2B promotes M2 macrophage activation and inflammation in children with asthma through stabilizing BAZ2B pre-mRNA</article-title>. <source>J. Allergy Clin. Immunol</source>. <volume>147</volume>, <fpage>921</fpage>-<lpage>932.e9</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mahnke</surname>, <given-names>K</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance Antigen Presentation via Major Histocompatibility Complex Class II–Positive Lysosomal Compartments</article-title> <source>Journal of Cell Biology</source>. <ext-link ext-link-type="uri" xlink:href="https://rupress.org/jcb/article/151/3/673/21295/The-Dendritic-Cell-Receptor-for-Endocytosis-Dec">https://rupress.org/jcb/article/151/3/673/21295/The-Dendritic-Cell-Receptor-for-Endocytosis-Dec</ext-link>. <year>2000</year></mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sims</surname>, <given-names>A. C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Release of Severe Acute Respiratory Syndrome Coronavirus Nuclear Import Block Enhances Host Transcription in Human Lung Cells</article-title>. <source>J. Virol</source>. <volume>87</volume>, <fpage>3885</fpage>–<lpage>3902</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mitchell</surname>, <given-names>HD</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A Network Integration Approach to Predict Conserved Regulators Related to Pathogenicity of Influenza and SARS-CoV Respiratory Viruses</article-title> <source>PLOS ONE</source>. <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069374">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069374</ext-link>. <year>2013</year></mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gómez-Carballa</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>A multi-tissue study of immune gene expression profiling highlights the key role of the nasal epithelium in COVID-19 severity</article-title>. <source>Environ. Res</source>. <volume>210</volume>, <fpage>112890</fpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Policard</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Jain</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Rego</surname>, <given-names>S.</given-names></string-name> &amp; <string-name><surname>Dakshanamurthy</surname>, <given-names>S.</given-names></string-name></person-group> <article-title>Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism</article-title>. <source>Virus Res</source>. <volume>301</volume>, <fpage>198464</fpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wei</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection</article-title>. <source>Cell</source> <volume>184</volume>, <fpage>76</fpage>-<lpage>91.e13</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wei</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection</article-title>. <source>Nat. Genet</source>. <volume>55</volume>, <fpage>471</fpage>–<lpage>483</lpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pereira</surname>, <given-names>A. C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Genetic risk factors and COVID-19 severity in Brazil: results from BRACOVID study</article-title>. <source>Hum. Mol. Genet</source>. <volume>31</volume>, <fpage>3021</fpage>–<lpage>3031</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname>, <given-names>X.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>ZBTB7A promotes virus-host homeostasis during human coronavirus 229E infection</article-title>. <source>Cell Rep</source>. <volume>41</volume>, <fpage>111540</fpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gupta</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Emerging role of ZBTB7A as an oncogenic driver and transcriptional repressor</article-title>. <source>Cancer Lett</source>. <volume>483</volume>, <fpage>22</fpage>–<lpage>34</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yoneyama</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300</article-title>. <source>EMBO J</source>. <volume>17</volume>, <fpage>1087</fpage>–<lpage>1095</lpage> (<year>1998</year>).</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>, <given-names>Q.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>SARS-CoV-2 infection activates CREB/CBP in cellular cyclic AMP-dependent pathways</article-title>. <source>J. Med. Virol</source>. <volume>95</volume>, <fpage>e28383</fpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Horowitz</surname>, <given-names>J. E.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease</article-title>. <source>Nat. Genet</source>. <volume>54</volume>, <fpage>382</fpage>–<lpage>392</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harris</surname>, <given-names>P. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support</article-title>. <source>J. Biomed. Inform</source>. <volume>42</volume>, <fpage>377</fpage>–<lpage>381</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harris</surname>, <given-names>P. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The REDCap consortium: Building an international community of software platform partners</article-title>. <source>J. Biomed. Inform</source>. <volume>95</volume>, <fpage>103208</fpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Purcell</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses</article-title>. <source>Am. J. Hum. Genet</source>. <volume>81</volume>, <fpage>559</fpage>–<lpage>575</lpage> (<year>2007</year>).</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alexander</surname>, <given-names>D. H.</given-names></string-name>, <string-name><surname>Novembre</surname>, <given-names>J.</given-names></string-name> &amp; <string-name><surname>Lange</surname>, <given-names>K.</given-names></string-name></person-group> <article-title>Fast model-based estimation of ancestry in unrelated individuals</article-title>. <source>Genome Res</source>. <volume>19</volume>, <fpage>1655</fpage>–<lpage>1664</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Auton</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>A global reference for human genetic variation</article-title>. <source>Nature</source> <volume>526</volume>, <fpage>68</fpage>–<lpage>74</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mao</surname>, <given-names>X.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>A Genomewide Admixture Mapping Panel for Hispanic/Latino Populations</article-title>. <source>Am. J. Hum. Genet</source>. <volume>80</volume>, <fpage>1171</fpage>–<lpage>1178</lpage> (<year>2007</year>).</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wojcik</surname>, <given-names>G. L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Genetic analyses of diverse populations improves discovery for complex traits</article-title>. <source>Nature</source> <volume>570</volume>, <fpage>514</fpage>–<lpage>518</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname>, <given-names>X.</given-names></string-name> &amp; <string-name><surname>Davis</surname>, <given-names>J. W.</given-names></string-name></person-group> <article-title>SAIGEgds—an efficient statistical tool for large-scale PheWAS with mixed models</article-title>. <source>Bioinformatics</source> <volume>37</volume>, <fpage>728</fpage>–<lpage>730</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>, <given-names>W.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies</article-title>. <source>Nat. Genet</source>. <volume>50</volume>, <fpage>1335</fpage>–<lpage>1341</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Willer</surname>, <given-names>CJ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>METAL: fast and efficient meta-analysis of genomewide association scans</article-title> <source>Bioinformatics</source>. <ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/bioinformatics/article/26/17/2190/198154">https://academic.oup.com/bioinformatics/article/26/17/2190/198154</ext-link>. <year>2010</year></mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McGuire</surname>, <given-names>D.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Model-based assessment of replicability for genome-wide association meta-analysis</article-title>. <source>Nat. Commun</source>. <volume>12</volume>, <fpage>1964</fpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Watanabe</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Taskesen</surname>, <given-names>E.</given-names></string-name>, van <string-name><surname>Bochoven</surname>, <given-names>A.</given-names></string-name> &amp; <string-name><surname>Posthuma</surname>, <given-names>D.</given-names></string-name></person-group> <article-title>Functional mapping and annotation of genetic associations with FUMA</article-title>. <source>Nat. Commun</source>. <volume>8</volume>, <fpage>1826</fpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Leeuw</surname>, <given-names>CA</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>MAGMA: Generalized Gene-Set Analysis of GWAS Data</article-title> <source>PLOS Computational Biology</source>. <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004219">https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004219</ext-link>. <year>2015</year></mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghoussaini</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics</article-title>. <source>Nucleic Acids Res</source>. <volume>49</volume>, <fpage>D1311</fpage>–<lpage>D1320</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McLaren</surname>, <given-names>W.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The Ensembl Variant Effect Predictor</article-title>. <source>Genome Biol</source>. <volume>17</volume>, <fpage>122</fpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barbeira</surname>, <given-names>A. N.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Exploiting the GTEx resources to decipher the mechanisms at GWAS loci</article-title>. <source>Genome Biol</source>. <volume>22</volume>, <fpage>49</fpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="data"><person-group person-group-type="author"><string-name><surname>Barbeira</surname>, <given-names>A. N.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>GWAS and GTEx QTL integration</article-title>. <source>Zenodo</source> <pub-id pub-id-type="doi">10.5281/zenodo.3518299</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barbeira</surname>, <given-names>A. N.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics</article-title>. <source>Nat. Commun</source>. <volume>9</volume>, <fpage>1825</fpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barbeira</surname>, <given-names>A. N.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Integrating predicted transcriptome from multiple tissues improves association detection</article-title>. <source>PLOS Genet</source>. <volume>15</volume>, <fpage>e1007889</fpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kachuri</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Gene expression in African Americans, Puerto Ricans and Mexican Americans reveals ancestry-specific patterns of genetic architecture</article-title>. <source>Nat. Genet</source>. <volume>55</volume>, <fpage>952</fpage>–<lpage>963</lpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bryc</surname>, <given-names>K</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Genome-wide patterns of population structure and admixture among Hispanic/Latino populations</article-title> <source>PNAS</source>. <ext-link ext-link-type="uri" xlink:href="https://www.pnas.org/doi/10.1073/pnas.0914618107">https://www.pnas.org/doi/10.1073/pnas.0914618107</ext-link>. <year>2010</year></mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.93666.2.sa4</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Siming</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Dartmouth College</institution>
</institution-wrap>
<city>Lebanon</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Solid</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>The authors conduct a <bold>valuable</bold> GWAS meta-analysis for COVID-19 hospitalization in admixed American populations and prioritized risk variants and genes. The evidence supporting the claims of the authors is <bold>solid</bold>. The work will be of interest to scientists studying the genetic basis of COVID pathogenesis.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.93666.2.sa3</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>This paper conducted a GWAS meta-analysis for COVID-19 hospitalization among admixed American populations. The authors identified four genome-wide significant associations, including two novel loci (BAZ2B and DDIAS), and an additional risk locus near CREBBP using cross-ancestry meta-analysis. They utilized multiple strategies to prioritize risk variants and target genes. Finally, they constructed and assessed a polygenic risk score model with 49 variants associated with critical COVID-19 conditions.</p>
<p>Strengths:</p>
<p>Given that most of the previous studies were done in European ancestries, this study provides unique findings about the genetics of COVID-19 in admixed American populations. The GWAS data would be a valuable resource for the community. The authors conducted comprehensive analyses using multiple different strategies, including Bayesian fine mapping, colocalization, TWAS, etc., to prioritize risk variants and target genes. The polygenic risk score (PGS) result demonstrated the ability of cross-population PGS model for COVID-19 risk stratification.</p>
<p>Weaknesses:</p>
<p>(1) One of the major limitations of this study is that the GWAS sample size is relatively small, which limits its power.</p>
<p>
(2) Lack of replication cohort.</p>
<p>
(3) Colocalization and TWAS used eQTL data from GTEx data, which are mainly from European ancestries.</p>
<p>Comments on latest version:</p>
<p>The authors addressed most of my concerns.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.93666.2.sa2</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>This is a genome-wide association study of COVID-19 in individuals of admixed American ancestry (AMR) recruited from Brazil, Colombia, Ecuador, Mexico, Paraguay and Spain. After quality control and admixture analysis, a total of 3,512 individuals were interrogated for 10,671,028 genetic variants (genotyped + imputed). The genetic association results for these cohorts were meta-analyzed with the results from The Host Genetics Initiative (HGI), involving 3,077 cases and 66,686 controls. The authors found two novel genetic loci associated with COVID-19 at 2q24.2 (rs13003835) and 11q14.1 (rs77599934), and other two independent signals at 3p21.31 (rs35731912) and 6p21.1 (rs2477820) already reported as associated with COVID-19 in previous GWASs. Additional meta-analysis with other HGI studies also suggested risk variants near CREBBP, ZBTB7A and CASC20 genes.</p>
<p>Strengths:</p>
<p>These findings rely on state-of-the-art methods in the field of Statistical Genomics and help to address the issue of low number of GWASs in non-European populations, ultimately contributing to reduce health inequalities across the globe.</p>
<p>Weaknesses:</p>
<p>There is no replication cohort, as acknowledged by the authors (page 29, line 587) and no experimental validation to assess the biological effect of putative causal variants/genes. Thus, the study provides good evidence of association, rather than causation, between the genetic variants and COVID-19.</p>
<p>Comments on latest version:</p>
<p>The issues identified in the first round of review were well addressed by the authors in the revised version of the manuscript.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.93666.2.sa1</article-id>
<title-group>
<article-title>Reviewer #3 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>In the context of the SCOURGE consortium's research, the authors conduct a GWAS meta-analysis on 4,702 hospitalized individuals of admixed American descent suffering from COVID-19. This study identified four significant genetic associations, including two loci initially discovered in Latin American cohorts. Furthermore, a trans-ethnic meta-analysis highlighted an additional novel risk locus in the CREBBP gene, underscoring the critical role of genetic diversity in understanding the pathogenesis of COVID-19.</p>
<p>Strengths:</p>
<p>(1) The study identified two novel severe COVID-19 loci (BAZ2B and DDIAS) by the largest GWAS meta-analysis for COVID-19 hospitalization in admixed Americans.</p>
<p>
(2) With a trans-ethnic meta-analysis, an additional risk locus near CREBBP was identified.</p>
<p>Weaknesses:</p>
<p>(1) The GWAS power is limited due to the relatively small number of cases.</p>
<p>(2) There is no replication study for the novel severe COVID-19 loci, which may lead to false positive findings.</p>
<p>(3) The variants selected for the PGS appear arbitrary and may not leverage the GWAS findings.</p>
<p>(4) The TWAS models were predominantly trained on European samples, and there is no replication study for the findings as well.</p>
</body>
</sub-article>
<sub-article id="sa4" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.93666.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Diz-de Almeida</surname>
<given-names>Silvia</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cruz</surname>
<given-names>Raquel</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Luchessi</surname>
<given-names>Andre D</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lorenzo-Salazar</surname>
<given-names>José M</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Heredia</surname>
<given-names>Miguel López</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Quintela</surname>
<given-names>Inés</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>González-Montelongo</surname>
<given-names>Rafaela</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Silbiger</surname>
<given-names>Vivian N</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Porras</surname>
<given-names>Marta Sevilla</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tenorio Castaño</surname>
<given-names>Jair Antonio</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nevado</surname>
<given-names>Julian</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aguado</surname>
<given-names>Jose María</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aguilar</surname>
<given-names>Carlos</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aguilera-Albesa</surname>
<given-names>Sergio</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almadana</surname>
<given-names>Virginia</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almoguera</surname>
<given-names>Berta</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alvarez</surname>
<given-names>Nuria</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Andreu-Bernabeu</surname>
<given-names>Álvaro</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arana-Arri</surname>
<given-names>Eunate</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arango</surname>
<given-names>Celso</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arranz</surname>
<given-names>María J</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Artiga</surname>
<given-names>Maria-Jesus</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baptista-Rosas</surname>
<given-names>Raúl C</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Barreda- Sánchez</surname>
<given-names>María</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Belhassen-Garcia</surname>
<given-names>Moncef</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bezerra</surname>
<given-names>Joao F</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bezerra</surname>
<given-names>Marcos AC</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boix-Palop</surname>
<given-names>Lucía</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brion</surname>
<given-names>María</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brugada</surname>
<given-names>Ramón</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bustos</surname>
<given-names>Matilde</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Calderón</surname>
<given-names>Enrique J</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carbonell</surname>
<given-names>Cristina</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Castano</surname>
<given-names>Luis</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Castelao</surname>
<given-names>Jose E</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conde-Vicente</surname>
<given-names>Rosa</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cordero-Lorenzana</surname>
<given-names>M Lourdes</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cortes-Sanchez</surname>
<given-names>Jose L</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Corton</surname>
<given-names>Marta</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Darnaude</surname>
<given-names>M Teresa</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Martino-Rodríguez</surname>
<given-names>Alba</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>del Campo-Pérez</surname>
<given-names>Victor</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Bustamante</surname>
<given-names>Aranzazu Diaz</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Domínguez-Garrido</surname>
<given-names>Elena</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eirós</surname>
<given-names>Rocío</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fariñas</surname>
<given-names>María Carmen</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernandez-Nestosa</surname>
<given-names>María J</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernández-Robelo</surname>
<given-names>Uxía</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernández-Rodríguez</surname>
<given-names>Amanda</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernández-Villa</surname>
<given-names>Tania</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gago-Domínguez</surname>
<given-names>Manuela</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gil-Fournier</surname>
<given-names>Belén</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gómez-Arrue</surname>
<given-names>Javier</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Álvarez</surname>
<given-names>Beatriz González</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bernaldo de Quirós</surname>
<given-names>Fernan Gonzalez</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>González-Neira</surname>
<given-names>Anna</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>González-Peñas</surname>
<given-names>Javier</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gutiérrez-Bautista</surname>
<given-names>Juan F</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Herrero</surname>
<given-names>María José</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Herrero-Gonzalez</surname>
<given-names>Antonio</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jimenez-Sousa</surname>
<given-names>María A</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lattig</surname>
<given-names>María Claudia</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Borja</surname>
<given-names>Anabel Liger</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lopez-Rodriguez</surname>
<given-names>Rosario</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mancebo</surname>
<given-names>Esther</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martín-López</surname>
<given-names>Caridad</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martín</surname>
<given-names>Vicente</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez-Nieto</surname>
<given-names>Oscar</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez-Lopez</surname>
<given-names>Iciar</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez-Resendez</surname>
<given-names>Michel F</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez-Perez</surname>
<given-names>Ángel</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mazzeu</surname>
<given-names>Juliana F</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Macías</surname>
<given-names>Eleuterio Merayo</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Minguez</surname>
<given-names>Pablo</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cuerda</surname>
<given-names>Victor Moreno</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oliveira</surname>
<given-names>Silviene F</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ortega-Paino</surname>
<given-names>Eva</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parellada</surname>
<given-names>Mara</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paz-Artal</surname>
<given-names>Estela</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Santos</surname>
<given-names>Ney PC</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pérez-Matute</surname>
<given-names>Patricia</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perez</surname>
<given-names>Patricia</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pérez-Tomás</surname>
<given-names>M Elena</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perucho</surname>
<given-names>Teresa</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pinsach-Abuin</surname>
<given-names>Mel Lina</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pita</surname>
<given-names>Guillermo</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pompa-Mera</surname>
<given-names>Ericka N</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Porras-Hurtado</surname>
<given-names>Gloria L</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pujol</surname>
<given-names>Aurora</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>León</surname>
<given-names>Soraya Ramiro</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Resino</surname>
<given-names>Salvador</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernandes</surname>
<given-names>Marianne R</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodríguez-Ruiz</surname>
<given-names>Emilio</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodriguez-Artalejo</surname>
<given-names>Fernando</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodriguez-Garcia</surname>
<given-names>José A</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruiz-Cabello</surname>
<given-names>Francisco</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruiz-Hornillos</surname>
<given-names>Javier</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ryan</surname>
<given-names>Pablo</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Soria</surname>
<given-names>José Manuel</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Souto</surname>
<given-names>Juan Carlos</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tamayo</surname>
<given-names>Eduardo</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tamayo-Velasco</surname>
<given-names>Alvaro</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taracido-Fernandez</surname>
<given-names>Juan Carlos</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Teper</surname>
<given-names>Alejandro</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Torres-Tobar</surname>
<given-names>Lilian</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Urioste</surname>
<given-names>Miguel</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Valencia-Ramos</surname>
<given-names>Juan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yáñez</surname>
<given-names>Zuleima</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zarate</surname>
<given-names>Ruth</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Rojas</surname>
<given-names>Itziar</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruiz</surname>
<given-names>Agustín</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sánchez</surname>
<given-names>Pascual</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Real</surname>
<given-names>Luis Miguel</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<collab>SCOURGE Cohort Group</collab>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guillen-Navarro</surname>
<given-names>Encarna</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ayuso</surname>
<given-names>Carmen</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parra</surname>
<given-names>Esteban</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Riancho</surname>
<given-names>José A</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rojas-Martinez</surname>
<given-names>Augusto</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Flores</surname>
<given-names>Carlos</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lapunzina</surname>
<given-names>Pablo</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carracedo</surname>
<given-names>Ángel</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews.</p>
<disp-quote content-type="editor-comment">
<p><bold>Public Reviews:</bold></p>
<p><bold>Reviewer #1 (Public Review):</bold></p>
<p>Summary:</p>
<p>This paper conducted a GWAS meta-analysis for COVID-19 hospitalization among admixed American populations. The authors identified four genome-wide significant associations, including two novel loci (BAZ2B and DDIAS), and an additional risk locus near CREBBP using cross-ancestry meta-analysis. They utilized multiple strategies to prioritize risk variants and target genes. Finally, they constructed and assessed a polygenic risk score model with 49 variants associated with critical COVID-19 conditions.</p>
<p>Strengths:</p>
<p>Given that most of the previous studies were done in European ancestries, this study provides unique findings about the genetics of COVID-19 in admixed American populations. The GWAS data would be a valuable resource for the community. The authors conducted comprehensive analyses using multiple different strategies, including Bayesian fine mapping, colocalization, TWAS, etc., to prioritize risk variants and target genes. The polygenic risk score (PGS) result demonstrated the ability of the cross-population</p>
<p>PGS model for COVID-19 risk stratification.</p>
</disp-quote>
<p>Thank you very much for the positive comments and the willingness to revise this manuscript.</p>
<disp-quote content-type="editor-comment">
<p>Weaknesses:</p>
<p>(1) One of the major limitations of this study is that the GWAS sample size is relatively small, which limits its power.</p>
<p>(2) The fine mapping section is unclear and there is a lack of information. The authors assumed one causal signal per locus, and only provided credible sets, but did not provide posterior inclusion probabilities (PIP) for the variants to be causal.</p>
<p>(3) Colocalization and TWAS used eQTL data from GTEx data, which are mainly from European ancestries. It is unclear how much impact the ancestry mismatch would have on the result. The readers should be cautious when interpreting the results and designing follow-up studies.</p>
</disp-quote>
<p>We agree with that the sample size is relatively small. Despite that, it was sufficient to reveal novel risk loci supporting the robustness of the main findings. We have indicated this limitation at the end of the discussion section.</p>
<p>Thank you for rising this point. As suggested, we have also used SuSIE, which allows to assume more than one causal signal per locus. However, in this case the results were not different from those obtained with the original Bayesian colocalization performed with corrcoverage. Regarding the PIP, at the fine mapping stage we are inclined to put more weight on the functional annotations of the variants in the credible set than on the statistical contributions to the signal. This is the reason why we prefer not to put weight on the PIP of the variants but prioritize variants that were enriched functional annotations.</p>
<p>This is a good point regarding the lack of diversity in GTEx data. We have also used data from AMR populations (GALA II-SAGE models), although it was only available for blood tissue. Regarding the ancestry mismatch between datasets, several studies have attempted to explore the impact. Gay et al. (PMID: 32912333) studied local ancestry effects on eQTLs from the GTEx consortium and concluded that adjustment of eQTLs by local ancestry only yields modest improvement over using global ancestry (as done in GTEx). Moreover, the colocalization results between adjusting by Local Ancestry and Global Ancestry were not significantly different. Besides, Mogil et al. (PMID: 30096133) observed that genes with higher heritability share genetic architecture between populations. Nevertheless, both studies have evidenced decreased power and poorer predictive performances regarding gene expression because of reduced diversity in eQTL analyses. As consequence of the ancestry mismatch, we now warn the readers that this may compromise signal detection (Discussion, lines 531-533).</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public Review):</bold></p>
<p>This is a genome-wide association study of COVID-19 in individuals of admixed American ancestry (AMR) recruited from Brazil, Colombia, Ecuador, Mexico, Paraguay, and Spain. After quality control and admixture analysis, a total of 3,512 individuals were interrogated for 10,671,028 genetic variants (genotyped + imputed). The genetic association results for these cohorts were meta-analyzed with the results from The Host Genetics Initiative (HGI), involving 3,077 cases and 66,686 controls. The authors found two novel genetic loci associated with COVID-19 at 2q24.2 (rs13003835) and 11q14.1 (rs77599934), and other two independent signals at 3p21.31 (rs35731912) and 6p21.1 (rs2477820) already reported as associated with COVID-19 in previous GWASs. Additional meta-analysis with other HGI studies also suggested risk variants near CREBBP, ZBTB7A, and CASC20 genes.</p>
<p>Strengths:</p>
<p>These findings rely on state-of-the-art methods in the field of Statistical Genomics and help to address the issue of a low number of GWASs in non-European populations, ultimately contributing to reducing health inequalities across the globe.</p>
</disp-quote>
<p>Thank you very much for the positive comments and the willingness to revise this manuscript.</p>
<disp-quote content-type="editor-comment">
<p>Weaknesses:</p>
<p>There is no replication cohort, as acknowledged by the authors (page 29, line 587), and no experimental validation to assess the biological effect of putative causal variants/genes. Thus, the study provides good evidence of association, rather than causation, between the genetic variants and COVID-19. Lastly, I consider it crucial to report the results for the SCOURGE Latin American GWAS, in addition to its meta-analysis with HGI results, since HGI data has a different phenotype scheme (Hospitalized COVID vs Population) compared to SCOURGE (Hospitalized COVID vs Non-hospitalized COVID).</p>
</disp-quote>
<p>We essentially agree with the reviewer in that one of the main limitations of the study is the lack of a replication stage because of the use of all available datasets on a one-stage analysis. To contribute to the interpretation of the findings in the absence of a replication stage, we now assessed the replicability of the novel loci using the Meta-Analysis Model-based Assessment of replicability (MAMBA) approach (PMID: 33785739) and included the posterior probabilities of replication in Table 2. We also explored further the potential replicability of signals in other populations. We agree that the results should be interpreted in terms of associations given the lack of functional validation of main findings, so we have slightly modified the discussion.</p>
<p>As suggested, the SCOURGE Latin American GWAS summary is now accessible by direct request to the Consortium GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/CIBERER/Scourge-COVID19">https://github.com/CIBERER/Scourge-COVID19</ext-link>) (lines 797-799). We have also included the results from the SCOURGE GWAS analysis for the replication of the 40 lead variants in the Supplementary Table 12. Results from the SCOURGE GWAS for the lead variants in the AMR meta-analysis with HGI were already included in the Supplementary Table 2. As note, we have not been able to conduct the meta-analysis with the same hospitalization scheme as in the HGI study since the population-specific results for those analyses were not publicly released. However, sensitivity analyses included within the supplementary material from the COVID-19 Host Genetics Initiative (2021) stated that there were no significant differences in effects (Odds Ratios) between analyses using population controls or just non-hospitalized COVID-19 patients.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Public Review):</bold></p>
<p>Summary:</p>
<p>In the context of the SCOURGE consortium's research, the authors conduct a GWAS meta-analysis on 4,702 hospitalized individuals of admixed American descent suffering from COVID-19. This study identified four significant genetic associations, including two loci initially discovered in Latin American cohorts. Furthermore, a trans-ethnic meta-analysis highlighted an additional novel risk locus in the CREBBP gene, underscoring the critical role of genetic diversity in understanding the pathogenesis of COVID-19.</p>
<p>Strengths:</p>
<p>(1) The study identified two novel severe COVID-19 loci (BAZ2B and DDIAS) by the largest GWAS meta-analysis for COVID-19 hospitalization in admixed Americans.</p>
<p>(2) With a trans-ethnic meta-analysis, an additional risk locus near CREBBP was identified.</p>
</disp-quote>
<p>Thank you very much for the positive comments and the willingness to revise this manuscript.</p>
<disp-quote content-type="editor-comment">
<p>Weaknesses:</p>
<p>(1) The GWAS power is limited due to the relatively small number of cases.</p>
<p>(2) There is no replication study for the novel severe COVID-19 loci, which may lead to false positive findings.</p>
</disp-quote>
<p>We agree with that the sample size is relatively small. Despite that, it was sufficient to reveal novel risk loci supporting the robustness of the main findings. We have indicated this limitation at the end of the discussion section.</p>
<p>Regarding the lack of a replication study, we now assessed the replicability of the novel loci using the Meta-Analysis Model-based Assessment of replicability (MAMBA) approach (PMID: 33785739). We have included the posterior probabilities of replication in Table 2.</p>
<disp-quote content-type="editor-comment">
<p>(3) Significant differences exist in the ages between cases and controls, which could potentially introduce biased confounders. I'm curious about how the authors treated age as a covariate. For instance, did they use ten-year intervals? This needs clarification for reproducibility.</p>
</disp-quote>
<p>Thank you for rising this point. Age was included as a continuous variable. This has been now indicated in line 667 (within Material and Methods).</p>
<disp-quote content-type="editor-comment">
<p>(4)&quot;Those in the top PGS decile exhibited a 5.90-fold (95% CI=3.29-10.60, p=2.79x10-9) greater risk compared to individuals in the lowest decile&quot;. I would recommend comparing with the 40-60% PGS decile rather than the lowest decile, as the lowest PGS decile does not represent 'normal controls'.</p>
</disp-quote>
<p>Thank you. In the revised version, the PGS categories was compared following the recommendation (lines 461-463).</p>
<disp-quote content-type="editor-comment">
<p>(5) In the field of PGS, it's common to require an independent dataset for training and testing the PGS model. Here, there seems to be an overfitting issue due to using the same subjects for both training and testing the variants.</p>
</disp-quote>
<p>We are sorry for the misunderstanding. In fact, we have followed the standard to avoid overfitting of the PGS model and have used different training and testing datasets. The training data (GWAS) was the HGI-B2 ALL meta-analysis, in which our AMR GWAS was not included. The PRS model was then tested in the SCOURGE AMR cohort. However, it is true that we did test the combination of the PRS adding the new discovered variants in the SCOURGE cohort. To avoid potential overfitting by adding the new loci, we have excluded from the manuscript the results on which we included the newly discovered variants.</p>
<disp-quote content-type="editor-comment">
<p>(6) The variants selected for the PGS appear arbitrary and may not leverage the GWAS findings without an independent training dataset.</p>
</disp-quote>
<p>Again, we are sorry for the misunderstanding. The PGS model was built with 43 variants associated with hospitalization or severity within the HGI v7 results and 7 which were discovered by the GenOMICC consortium in their latest study and were not in the latest HGI release. The variants are included within the Supplementary Table 14, but we have now annotated the discovery GWAS.</p>
<disp-quote content-type="editor-comment">
<p>(7) The TWAS models were predominantly trained on European samples, and there is no replication study for the findings as well.</p>
</disp-quote>
<p>This is a good point regarding the lack of diversity in GTEx data. We have also used data from AMR populations (GALA II-SAGE models), although it was only available for blood tissue. Regarding the ancestry mismatch between datasets, several studies have attempted to explore the impact. Gay et al. (PMID: 32912333) studied local ancestry effects on eQTLs from the GTEx consortium and concluded that adjustment of eQTLs by local ancestry only yields modest improvement over using global ancestry (as done in GTEx). Moreover, the colocalization results between adjusting by Local Ancestry and Global Ancestry were not significantly different. Besides, Mogil et al. (PMID: 30096133) observed that genes with higher heritability share genetic architecture between populations. Nevertheless, both studies have evidenced decreased power and poorer predictive performances regarding gene expression because of reduced diversity in eQTL analyses. As consequence of the ancestry mismatch, we now warn the readers that this may compromise signal detection (Discussion, lines 531-533).</p>
<disp-quote content-type="editor-comment">
<p><bold>Recommendations for the authors:</bold></p>
<p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p>
<p>(1) The authors mentioned the fine mapping method did not converge for the locus in chr 11. I would consider trying a different fine-mapping method (such as SuSiE or FINEMAP). It would be helpful to provide posterior inclusion probabilities (PIP) for the variants in fine mapping results and plot the PIP values in the regional association plots.</p>
</disp-quote>
<p>As suggested, we have also used SuSIE, which allows to assume more than one causal signal per locus. However, in this case the results were not different from those obtained with the original Bayesian colocalization performed with corrcoverage. SuSIE’s fine-mapping for chromosome 11 prioritized a single variant, which is likely due to the rare frequency. Thus, we have maintained the fine-mapping as it was originally indicated in the previous version of the manuscript but have now included the credible set in Supplementary Table 6.</p>
<p>Regarding the PIP, at the fine mapping stage we are inclined to put more weight on the functional annotations of the variants in the credible set than on the statistical contributions to the signal. This is the reason why we prefer not to put weight on the PIP of the variants but prioritize variants that were enriched functional annotations.</p>
<disp-quote content-type="editor-comment">
<p>(2) Please provide more detailed information about the VEP and V2G analysis and how to interpret those results. My understanding of V2G is that it includes different sources of information (such as molecular QTLs and chromatin interactions from different tissues/cell types, etc.). It is unclear what sources of information and weight settings were used in the V2G model.</p>
</disp-quote>
<p>Thank you for rising this point. As suggested, we have clarified the basis for VEP and V2G and the interpretation (lines 732-743).</p>
<disp-quote content-type="editor-comment">
<p>(3) The authors identified multiple genes with different strategies, e.g. FUMA, V2G, COLOC, TWAS, etc. How many genes were found/supported by evidence provided by multiple methods? It could be helpful to have a table summarizing the risk genes found by different strategies, and the evidence supporting the genes. e.g. which genes are found by which methods, and the biological functions of the genes, etc.</p>
</disp-quote>
<p>Thank you for rising this point. As suggested, we now added a new figure (Figure 5) to summarize the findings with the multiple methods used.</p>
<disp-quote content-type="editor-comment">
<p>(4) It would be helpful to make the code/scripts available for reproducibility.</p>
</disp-quote>
<p>As suggested, the SCOURGE Latin American GWAS summary and the analysis scripts (<ext-link ext-link-type="uri" xlink:href="https://github.com/CIBERER/Scourge-COVID19/tree/main/scripts/novel-risk-hosp-AMR-2024">https://github.com/CIBERER/Scourge-COVID19/tree/main/scripts/novel-risk-hosp-AMR-2024</ext-link>) are now accessible in the Consortium GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/CIBERER/Scourge-COVID19">https://github.com/CIBERER/Scourge-COVID19</ext-link>) (lines 806-807).</p>
<disp-quote content-type="editor-comment">
<p>(5) The fonts in some of the figures (e.g. Figure 2) are hard to read.</p>
</disp-quote>
<p>Thank you. We have now included the figures as SVG files.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p>
<p>- The abstract lacks a conclusion sentence.</p>
</disp-quote>
<p>Thank you. As suggested, we have included two additional sentences with broad conclusions from the study. We preferred to avoid relying on conclusions related to known or new biological links of the prioritized genes given the lack of functional validation of main findings.</p>
<disp-quote content-type="editor-comment">
<p>- Regarding the association analysis (page 27, line 677), I wonder if some of the 10 principal components (PCs) are capturing information about the recruitment areas (countries). It may be relevant to test for multicollinearity among these variables.</p>
</disp-quote>
<p>Since we acknowledge that some of the categories might be correlated with a certain PC but not all of them do, we have calculated GVIF values for the main variables to assess the categorical variable as a single entity. The scaled GVIF^1(1/2*Df)) value for the categorical variable is 1.52. Thus, if we square this value, we obtain 2.31, which can be then used for applying usual rule-of-thumb for VIF values.</p>
<disp-quote content-type="editor-comment">
<p>- Still on the topic of association analysis, did the authors adjust the logistic model for comorbidities variables from Table 1? Given these comorbidities also have a genetic component and their distribution differs between non-hospitalized vs hospitalized, I am concerned that comorbidities might be confounding the association between genetic variants and COVID.</p>
</disp-quote>
<p>We did not adjust by comorbidities since HGI studies were not adjusted either and we aimed to be as aligned as possible with HGI. However, as suggested, we have now tested the association between each of the comorbidities in Table 1 and each of the variants in Table 2, using the comorbidities as dependent variables and adjusting for the main covariables (age, sex, PCs and country of recruitment). None of the variants were significantly associated to the comorbidities (line 333).</p>
<disp-quote content-type="editor-comment">
<p>- If I understood correctly, the 49 genetic variants used to develop the polygenic risk score model (PRS) were based on the HGI total sample size (data release 7), which is predominantly of European ancestry. I am concerned about the prediction accuracy in the AMR population (PRS transferability issue).</p>
</disp-quote>
<p>We have explored literature in search of other PRS to compare the associated OR in our cohort with ORs calculated in European populations. Horowitz et al. (2022) reported an OR of 1.38 for the top 10% with respect to hospitalization risk in European individuals using a GRS with 12 variants.</p>
<p>We acknowledge that this might be an issue and is now explained in discussion of the revised version (lines 561-568). However, as this is the first time a PRS for COVID-19 is applied to a relatively large AMR cohort, we believe that this analysis will be of value for further analyses regarding PRS transferability, providing a source for comparison in further studies.</p>
<disp-quote content-type="editor-comment">
<p>- On page 23, line 579, the authors acknowledge their &quot;GWAS is underpowered&quot;. This sentence requires a sample/power calculation, otherwise, I suggest using &quot;is likely underpowered&quot;.</p>
</disp-quote>
<p>Thanks for the input. We have modified the sentence as suggested.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p>
<p>I wonder if the authors have an approximate date when the GWAS summary statistic will be available. I reviewed some manuscripts in the past, and the authors claimed they would deposit the data soon, but in fact it would not happen until 2 years later.</p>
</disp-quote>
<p>The summary statistics are already available from the SCOURGE Consortium repository <ext-link ext-link-type="uri" xlink:href="https://github.com/CIBERER/Scourge-COVID19">https://github.com/CIBERER/Scourge-COVID19</ext-link> (lines 806-807).</p>
</body>
</sub-article>
</article>